株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

低分子がん治療薬の世界市場:治療薬価格、投与量、臨床試験洞察(2026年)

Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026

発行 KuicK Research 商品コード 944219
出版日 ページ情報 英文 753 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

低分子がん治療薬の世界市場:治療薬価格、投与量、臨床試験洞察(2026年) Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026
出版日: 2020年06月25日 ページ情報: 英文 753 Pages
担当者のコメント
低分子ベースの抗がん剤の研究開発はさらに今後加速していくことが予想されており、治療方法、市場、パイプライン分析など、700ページを超えるボリュームでまとめられた分析レポートです。
概要

世界の小分子抗がん剤市場は、今後6年間で倍増し、新薬の発売と大規模な臨床パイプラインにより、1,300億米ドルに達すると予測されています。今後の市場シナリオは、低分子ベースの抗がん剤の研究、開発、商業化の可能性にとって有望なものになると考えられています。基本的なターゲティングの優位性と、がんの臨床パイプラインにおける低分子医薬品の優位性が、今後数年で世界の低分子抗がん剤市場を牽引すると見込まれています。

当レポート、世界の低分子がん治療薬市場:治療薬価格、投与量、臨床試験洞察2026年は、市場の機会、シェア、臨床試験の概要、小分子がん治療薬に関する洞察、フェーズ・処方・企業・国・作用機序・適応症別の市場分析、Covid-19による市場への影響、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 小薬物分子のイントロダクション

第2章 低分子医薬品の必要性

第3章 がん小分子薬と他の利用可能な治療法の比較

  • 小分子がん治療薬と他の治療薬パラメーターとの比較
  • 小分子がん治療薬と免疫療法
  • 小分子がん治療薬と化学療法
  • 小分子がん治療薬対放射線療法
  • 小分子がん治療薬とがん細胞の外科的除去の比較

第4章 新興がん治療薬としての小薬物分子

  • 小分子薬とがん治療との関係
  • 癌治療において小分子薬が標的とするメカニズム
    • がん治療のための成長因子キナーゼ阻害剤としての小分子薬
    • がん治療のためのDNA損傷応答阻害剤としての小分子薬
  • 小分子阻害剤とその関連経路

第5章 市場動向と機会

  • 米国
  • 欧州
  • アジア
  • その他の地域

第6章 臨床パイプラインの概要

  • フェーズ別
  • 処方別
  • 企業別
  • 国別
  • 適応症別
  • 作用機序別

第7章 市場分析:教育レベルでの小分子がん治療薬調査

  • IACS-10759:MD Andersonでの小分子創薬
  • Yale 大学の研究者によるにBET低分子インヒビターの発見
  • Amgen&Miratiの低分子がん治療薬:異なるがんタイプのKRAS遺伝子に対する抗がん剤
  • AOH1160:University of Californiaの乳がんに着目した低分子研究

第8章 市場分析:市場拡大に向けた提携・協業

  • IACSとX-Chemが低分子がん治療薬の開発に着手
  • MD Anderson、Artios PharmaおよびShangPharmaの低分子ATR阻害剤プログラムでの協業
  • Aptose BiosciencesとMoffitt Cancer Centerの新規マルチターゲットエピジェネティック治療薬の開発に向けた戦略的提携の実施
  • Merckと大鵬薬品の小型KRASを標的としたがん治療薬の共同研究開始

第9章 市場成長要因と課題

  • 市場を牽引する潜在的な洞察
  • 市場成長に関する課題

第10章 がん研究領域における市場の将来の洞察

第11章 Covid-19の市場への影響

第12章 乳がんのための小分子治療薬:可用性、投与量、価格分析

  • Ribociclib (Kisqali)
  • Alpelisib (Piqray)
  • Abemaciclib (Verzenio)
  • Talazoparib (Telzenna)
  • Nertinib (Nerlynx)
  • Palbociclib (Ibrance)
  • Ixabepilone (Ixempra)
  • Anastrazole (Arimidex)
  • Lapatinib (Tykerb)
  • Toremifene (Fareston)
  • Letrozole (Femara)
  • Raloxifene (Evista)
  • Tamoxifen Oral Liquid (Soltamax)
  • Exemestane (Aromasin)
  • Testosterone Cypionate (Depo-Testosterone)
  • Fluoxymesterone (Halotestine/Androxy)
  • Fadrozole (Afema)
  • Tamibarotene (Amnolake)
  • Testosterone Propionate

第13章 白血病のための小分子治療薬:可用性、投与量、価格分析

  • Gilteritinib (Xospata)
  • Venetoclax (Venclexta)
  • Bosutinib (Bosulif)
  • Nilotinib (Tasigna)
  • Tretinoin (Vesanoid)
  • Clofarabine (Clolar)
  • Cytarabine/Daunorubicin (Vyxeos)
  • Dasatinib (Sprycel)
  • Ponatinib (Iclusig)
  • Enasidenib (Idhifa)
  • Ivosidenib (Tibsovo)
  • Cladribine (Mavenclad/Leustatin)
  • Mercaptopurine Oral Suspension (Purixan)
  • Methotrexate Oral Solution (Xatmep)
  • Pentostatin (Nipent)
  • Arsenic Trioxide (Trisenox)
  • Quizartinib (Vanflyta)
  • Histamine Dihydrochloride Injection (Ceplene)
  • Ubenimix (Bestatin)
  • Omacetaxine Mepesuccinate (Synribo)
  • Radotinib (Supect)

第14章 肺癌のための小分子治療薬:可用性、投与量、価格分析

  • Gefitinib (Irresa)
  • Entrectinib (Rozlytrek)
  • Osimertinib (Tagrisso)
  • Erlotinib (Tarceva)
  • Brigatinib (Alunbirg)
  • Lorbrena (Lorlatinib)
  • Vinorelbine (Navelbine)
  • Zykadia (Certinib)
  • Pemetrexed (Alimta)
  • Alectinib (Alecensa)
  • Xalkori (Crizotinib)
  • Nintedanib (Ofev)
  • Anlotinib (Focus V)
  • Amrubicin (Calsed)
  • Icotinib (Conmana)

第15章 リンパ腫のための小分子治療薬:可用性、投与量、価格分析

  • Copanlisib (Aliqopa)
  • Methoxsalen Solution (Uvadex)
  • Pralatrexate (Folotyn)
  • Bexarotene Topical (Targretin Gel)
  • Pixantrone (Pixuvri)
  • Belinostat (Beleodaq)
  • Zanubrutinib (Brukinsa)
  • Vorinostat (Zolinza)
  • Romidepsin (Istodax)
  • Bexarotene (Targretin)
  • Mechlorethamine (Valchlor/Ledaga)

第16章 骨髄腫のための小分子治療薬:可用性、投与量、価格分析

  • Ixazomib (Ninlaro)
  • Melphalan Intravenous (Evomela/Chemostat)
  • Thalidomide (Thalomid)
  • Selinexor (Xpovio)
  • Panobinostat (Farydak)
  • Bortezomib (Velcade)
  • Pomalidomide (Pomalyst)
  • Dexamethasone High Dose (Neofordex)

第17章 前立腺癌のための小分子治療薬:可用性、投与量、価格分析

  • Xtandi (Enzalutamide)
  • Apalutamide (Erleada)
  • Ertafitinib (Balversa)
  • Darolutamide (Nubeqa)
  • Bicalutamide (Casodex)
  • Nilutamide (Nilandron)
  • Abiraterone (Zytiga)
  • Xofigo (Radium Ra 223 dichloride)
  • Pedeliporfin (Tookad)

第18章 胃癌のための小分子治療薬:可用性、投与量、価格分析

  • Avapritinib (Ayvakit)
  • Rivoceranib (Aitan)
  • Gimeracil/Oteracil/Tegafur (Teysuno/TS-1)
  • Eptaplatin/Heptaplatin

第19章 がん診断用のための小分子治療薬:可用性、投与量、価格分析

  • Fluciclovine 18F (Axumin)
  • Tc 99m Tilmanocept (Lymphoseek)
  • Perflubutane (Sonazoid)
  • Hexyl Aminolevulinate (Cysview)
  • Fluorocholine 18F (IASOcholine/Pcolina)
  • Gadobuterol (Gadavist)

第20章 皮膚がんのための小分子治療薬:可用性、投与量、価格分析

  • Benimetinib (Mektovi)
  • Cobimetinib (Cotellic)
  • Sonidegib (Odomzo)
  • Vismodegib (Erivedge)
  • Imiquimod (Aldara/Zyclara)
  • Amivolevulinic Acid (Ameluz)
  • Methyl Aminolevulinate (Metvixia/Metvix PDT)
  • Vemurafenib (Zelboraf)

第21章 膵臓癌のための小分子治療薬:可用性、投与量、価格分析

  • Irinotecan Liposome Injection (Onivyde)

第22章 甲状腺腫瘍のための小分子薬-入手可能性、投与量および価格分析

  • Vendetanib (Caprelsa)

第23章 腎癌のための小分子治療薬:可用性、投与量、価格分析

  • Axitinib (Inlyta)

第24章 大腸がんのための小分子治療薬:可用性、投与量、価格分析

  • Tipiracil/Trifluridine (Lonsurf)
  • Irinotecan (Camptosar)
  • Oxaliplatin (Eloxatin)
  • Raltitrexed (Tomudex)
  • Irinotecan-Eluting Beads (Paragon Beads/Debiri)
  • Fruquintinib (Elunate)

第25章 固形腫瘍のための小分子治療薬:可用性、投与量、価格分析

  • Larotectinib (Viktravi)

第26章 複数のがんを標的とする低分子医薬品:可用性、投与量、価格分析、販売分析

  • Fludarabin (Fludara/Oforta)
  • Gemcitabine (Gemzar)
  • Sorafnib (Nexavar)
  • Rucaparib (Rubraca)
  • Doxorubicin (Aridamycin)
  • Acalabrutinib (Calquence)
  • Ibrutinib (Imbruvica)
  • Azacitidine (Vidaza)
  • Lenalidomide (Revlimid)
  • Doxorubicin Liposomal (Doxil)
  • Tazemetostat (Tazverik)
  • Busulfan (Busulfex)
  • Afatinib (Gilotrif)
  • Gemcitabine (Infugem)
  • Carmustine Polifeprosan 20 wafer (Gliadel)
  • Eribulin (Halaven)
  • Paclitaxel-Protein Bound (Abraxane)
  • Trabectedine (Yondelis)
  • Paclitaxel (Taxol)
  • Docetaxel (Taxotere)
  • Idelalisib (Zydelig)
  • Duvelisib (Copiktra)
  • Regorafenib (Stivagra)
  • Nelarabine (Arranon)
  • Capecitabine (Xeloda)
  • Lenvatinib (Lenvima)
  • Olaparib (Lynparza)
  • Niraparib (Zejula)
  • Pazopanib (Votrient)
  • Alitretinoin Topical (Panretin)
  • Mitotane (Lysodren)
  • Valrubicin (Valstar)
  • Hydroxyurea (Hydrea)
  • Mitoxantrone (Novantrone)
  • Zoledronic Acid (Zometa/Reclast)
  • Fotemustine (Muforan)
  • Paclitaxel Nanoparticle (Nanoxel)
  • Topotecan (Hycamtin)
  • Decitabine (Decogen)
  • Tivozanib (Fotivda)
  • Telotristat Etiprate (Xermelo)
  • Imatinib (Gleevec)
  • Trametinib (Mekinist)
  • Cabozantinib (Cabometyx)
  • Encorafenib (Braftovi)
  • Dabrafenib (Tafinlar)
  • Sunintab (Sutent)
  • Levoleucovorin (Fusilev/Khapzory)
  • Bendamustine (Treanda/Belrapzo/Bendeka)
  • Forodesine (Fodosine/Mundesine)
  • Talaporfin (Laserphyrin)
  • Tucidinostat (Epidaza)
  • Doxorubicin Eluting Beads (DC Beads)
  • Temozolomide (Temodar)
  • Paclitaxel Polymeric Micelle Formulation (GenexolPM)
  • Docetaxel polymeric micelle (Nanoxel M)
  • Methotrexate
  • Treosulfan (Ovastat/Tercondi)
  • Belotecan (Camtobell)
  • Paclitaxel Liposomal(Lipusu/Bevetex)
  • Amsacrine (Amsa PD/Amekrin)
  • Cyclophosphamide
  • Docetaxel Nanosome (DoceAqualip)
  • Pamidronic acid (Aredia)
  • Mopidamol (Rapenton)
  • Nedaplatin (Aqupla)
  • Cytarabin/Cytarabin Liposomal (DepoCyt)
  • Dianhydrogalactitol (DAG for Injection)

第27章 競合情勢

  • Johnson & Johnson
  • Teva Pharmaceutical
  • Boehringer Ingelheim
  • Allergan
  • Pfizer
  • Bristol-Myers Squibb
  • Merck
  • GlaxoSmithKline
  • AstraZeneca
  • Gilead Sciences
図表

List of Figures

  • Figure 1-1: Difference in the Size of Small Molecule Drug & Large Molecule Drug
  • Figure 1-2: Comparison between Small Molecule Drugs & Others
  • Figure 1-3: Brief Description for Small Molecule Drug Discovery
  • Figure 2-1: Small Molecule Drug Entry through Cell Membrane vs. Large Molecule Drug Entry
  • Figure 3-1: Important Parameters for Small Molecule Cancer Drugs
  • Figure 3-2: Small Molecule Cancer Drugs vs. Immunotherapy Treatment Procedure
  • Figure 3-3: Side Effects Caused by Small Molecule Cancer Drugs & Chemotherapeutic Agents
  • Figure 3-4: Small Molecule Cancer Drug Mechanism vs. Radiation Therapy
  • Figure 3-5: Small Molecule Cancer Drug Mechanism vs. Surgical Removal of Cancer Cells
  • Figure 4-1: Specific Targets for Small Molecule Cancer Drugs
  • Figure 4-2: Cancer Cell Growth in Absence & Presence of Small Molecule Cancer Drugs
  • Figure 4-3: Small Molecule Cancer Drugs Inhibiting DNA Damage Repair System Response
  • Figure 4-4: Specific Molecular Targets & their Indications for Small Molecule Cancer Drugs
  • Figure 4-5: Small Molecule Cancer Drugs & their Targets
  • Figure 5-1: Global - Small Molecule Cancer Drug Market (US$ Billion), 2019 - 2026
  • Figure 5-2: Global - Small Molecule Cancer Drug Market by Region (%), 2019
  • Figure 5-3: Global - Small Molecule Cancer Drug Market by Region (%), 2026
  • Figure 5-4: Global - Small Molecule Cancer Drug Market by Region (US$ Billion), 2019
  • Figure 5-5: Global - Small Molecule Cancer Drug Market by Region (US$ Billion), 2026
  • Figure 5-6: US - Parameters Responsible for Dominant Small Molecule Cancer Market
  • Figure 5-7: Europe - Factors Favoring Small Molecule Cancer Market
  • Figure 5-8: Comparison between different Parameters for Small Molecule Cancer Drug Market
  • Figure 6-1: Global Small Molecule Cancer Drug Clinical Pipeline by Phase, (Number of Drugs), 2020
  • Figure 6-2: Global Small Molecule Cancer Drug Clinical Pipeline by Phase, (%), 2020
  • Figure 6-3: Global Small Molecule Cancer Drug Clinical Pipeline by Formulation (Number), 2020
  • Figure 6-4: Global Small Molecule Cancer Drug Clinical Pipeline by Company (Number), 2020
  • Figure 6-5: Global Small Molecule Cancer Drug Clinical Pipeline by Country (Number), 2020
  • Figure 6-6: Global Small Molecule Cancer Drug Clinical Pipeline by Indication (Number), 2020
  • Figure 6-7: Global Small Molecule Cancer Drug Clinical Pipeline by Indication (Number), 2020
  • Figure 9-1: Arrival of Small Molecule Cancer Drugs into the Cancer Market
  • Figure 9-2: Driving Factors for Small Molecule Cancer Market
  • Figure 12-1: Kisqali - FDA Approval Year by Indication
  • Figure 12-2: Kisqali - Patent Issue & Expiration Year
  • Figure 12-3: Kisqali - Price for Supply of 21, 42 & 63 Tablets of 200mg (US$), May'2020
  • Figure 12-4: Kisqali - Duration of Treatment Cycle by Phase
  • Figure 12-5: kisqali - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 12-6: Global - kisqali Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 12-7: Piqray - Patent Issue & Expiration Year
  • Figure 12-8: Piqray - Price for Supply of 56 Tablets & Price per unit Tablet of 200-50mg & 150mg (US$), May'2020
  • Figure 12-9: Piqray - Price for Supply of 28 Tablets & Price per unit Tablet of 200mg (US$), May'2020
  • Figure 12-10: Piqray - Recommended & Reduced Dose (mg/day), May'2020
  • Figure 12-11: Piqray - Quarterly Sales Value (US$ Million), Q3-Q4'2019 & Q1'2020
  • Figure 12-12: Verzenio - Patent Issue & expiration Year
  • Figure 12-13: Verzenio - Price for a Supply of 14 Tablets & Price per unit Tablet (US$), May'2020
  • Figure 12-14: Verzenio - Dose by Type of Therapy (mg/Twice daily), May'2020
  • Figure 12-15: Verzenio Monotherapy - Initial & Reduced Dose (mg/Twice daily), May'2020
  • Figure 12-16: Verzenio Combinational - Initial & Reduced Dose (mg/Twice daily), May'2020
  • Figure 12-17: Verzenio - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 12-18: Global - Verzenio Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 12-19: Telzenna - FDA Approval & Patent Expiration Year
  • Figure 12-20: Talzenna - Price for Supply of 30 Tablets & Price per unit Tablet of Various Dose Regimens (US$), May'2020
  • Figure 12-21: Telzenna - Initial & reduced Dose (mg), May'2020
  • Figure 12-22: Nertininb - FDA Approval & Patent Expiration Year
  • Figure 12-23: Nerlynx - Price for 12 Tablet Supply & Price per unit Tablet of 20mg Tablet (US$), May'2020
  • Figure 12-24: Global - Nerlynx Sales Value (US$ Million), 2018 & 2019
  • Figure 12-25: Global - Nerlynx Quarterly Sales Value (US$ Million), 2019
  • Figure 12-26: Ibrance - FDA Approval by Indication
  • Figure 12-27: Ibrance - Patent Issue & Expiration Year
  • Figure 12-28: Ibrance - Price for 21 Capsule & Price per unit Capsule (US$), May'2020
  • Figure 12-29: Ibrance - Recommended & Reduced Dose (mg/day)
  • Figure 12-30: Ibrance - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 12-31: Ibrance - Annual Sales Value by Region (US$ Million), 2019
  • Figure 12-32: Ibrance - Annual Sales Value by Region (%), 2019
  • Figure 12-33: Ibrance - Quarterly Sales value (US$ Million), 2018 & 2019
  • Figure 12-34: Ixempra - FDA Approval & Patent Expiration Year
  • Figure 12-35: Ixempra - Price for 15m & 45mg Powder for Injection (US$), May'2020
  • Figure 12-36: Ixempra - Average & Maximum Cost of Single Treatment Cycle (US$), May'2020
  • Figure 12-37: Arimidex - FDA Approval & Patent Expiration Year
  • Figure 12-38: Arimidex - Price for 30 Tablets Supply & Price per unit Tablet (US$), May'2020
  • Figure 12-39: Anastrazole - Average Price for 30 Tablets Supply & Price per unit Tablet (US$), May'2020
  • Figure 12-40: Tykerb - Patent Issue & Expiration Year
  • Figure 12-41: Tykerb - Price for 150 Tablets & Price per Unit Tablet of 150mg (US$), May'2020
  • Figure 12-42: Tykerb - Recommended Dose by Indication (mg/day)
  • Figure 12-43: Fareston - FDA Approval & First Generic Approval Year
  • Figure 12-44: Fareston - Price for 30 Tablets & price per unit Tablet of 60mg (US$), May'2020
  • Figure 12-45: Generic Toremifene - Price for 30 Tablets & price per unit Tablet of 60mg (US$), May'2020
  • Figure 12-46: Fareston - FDA Approval & First Generic Approval Year
  • Figure 12-47: Femara - Price for 30 Tablets & price per unit Tablet of 2.5 mg (US$), May'2020
  • Figure 12-48: Generic Toremifene - Price for Various Tablet Supplies of 2.5mg (US$), May'2020
  • Figure 12-49: Raloxifdene - FDA Approval & First Generic Approval Year
  • Figure 12-50: Evista - Price for 30 Tablets Supply & Price per Unit tablet (US$), May'2020
  • Figure 12-51: Evista - Price for 100 Tablets Supply & Price per Unit tablet (US$), May'2020
  • Figure 12-52: Generic Raloxifene - Price for Various Supplies of 60mg Tablet (US$), May'2020
  • Figure 12-53: Soltamax - Price for 150 ml Supply & Price per unit ml of Oral Solution (US$), June'2020
  • Figure 12-54: Soltamax - Minimum & Maximum Dose for Metastatic Breast Cancer Treatment (mg/day)
  • Figure 12-55: Soltamax - Minimum & Maximum Duration for Breast Cancer Treatment (Years)
  • Figure 12-56: Aromasin - FDA Approval & First Generic Approval Year
  • Figure 12-57: Aromasin - Price for 30 Tablet Supply & Price per unit Tablet (US$), June'2020
  • Figure 12-58: Generic Exemestane - Price for 30 Tablet Supply & Price per unit Tablet (US$), June'2020
  • Figure 12-59: Depo-testosterone - Price for 10ml & Price per ml of 100mg/ml Intramuscular Solution (US$), June'2020
  • Figure 12-60: Depo-testosterone - Price for 10ml & 1 ml Supplies of 200mg/ml Intramuscular Solution (US$), June'2020
  • Figure 12-61: Fluoxymesterone - FDA Approval Year by Brand Name
  • Figure 12-62: Androxy - Price for Supply of 100 Tablets & Price per unit Tablet (US$), June'2020
  • Figure 12-63: Fluoxymesterone - Minimum & Maximum Recommended Dose (mg), June'2020
  • Figure 12-64: Fluoxymesterone - Minimum & Maximum Cost of Daily Treatment (US$), June'2020
  • Figure 12-65: Afema- Price for Supply of 10mg & 50mg Powder (US$), June'2020
  • Figure 12-66: Amnolake - PMDA Approval & Patent Expiration Year
  • Figure 13-1: Xospata - Patent Issue Expiration Year
  • Figure 13-2: Xospata - Price for 30 Tablets & Price per unit Tablet (US$), May'2020
  • Figure 13-3: Xospata - Daily, Monthly & Annual Treatment Cost (US$), May'2020
  • Figure 13-4: Global - Xospata Quarterly Sales Value (JPY/US$ Million), 2018 & 2019
  • Figure 13-5: Venetoclax - Patent Issue & Expiration year
  • Figure 13-6: Venetoclax - Price for Various Supplies of 10mg Tablet (US$), May'2020
  • Figure 13-7: Venetoclax - Price for Various Supplies of 50mg Tablet (US$), May'2020
  • Figure 13-8: Venetoclax - Price for Various Supplies of 50mg Tablet (US$), May'2020
  • Figure 13-9: Venetoclax - Price for 42 Kit & Price per unit Kit (US$), May'2020
  • Figure 13-10: Venetoclax Monotherapy - Recommended Dose by Treatment Week for CLL Management (mg/day), May'2020
  • Figure 13-11: Venetoclax Combinational - Recommended Dose in Initial & Subsequent Treatment Cycle for CLL (mg/Cycle), May'2020
  • Figure 13-12: Venetoclax Monotherapy - Recommended Dose for AML (mg/day), May'2020
  • Figure 13-13: Venclexta - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 13-14: Venclexta - Annual Sales Value by Region (US$ Million), 2019
  • Figure 13-15: Venclexta - Annual Sales Value by Region (%), 2019
  • Figure 13-16: Global - Venclexta Quarterly Sales Value (US$ Million), 2019
  • Figure 13-17: Bosulif - Patent Issue & Expiration Year
  • Figure 13-18: Bosulif - Price for 120 Tablet & Price per Unit of 100mg Tablet (US$), May'2020
  • Figure 13-19: Bosulif - Price for 30 Tablet & Price per Unit of 400 & 500mg Tablet (US$), May'2020
  • Figure 13-20: Bosulif - Recommended Dose for Newly Diagnosed & Therapy Resisted CML (mg)
  • Figure 13-21: Tasigna - FDA Approval Year by Indication
  • Figure 13-22: Tasigna - Patent Issue & Expiration Year
  • Figure 13-23: Tasigna - Price for 120 Capsules & Price per unit Capsule of 50mg (US$), May'2020
  • Figure 13-24: Tasigna - Price for 28 & 112 Capsules & Price per unit Capsule of 100 & 200 mg (US$), May'2020
  • Figure 13-25: Tasigna - Recommended Dose by Indication (mg Twice Daily), May'2020
  • Figure 13-26: Tasigna - Recommended Pediatric Dose by Surface Area (mg Twice Daily), May'2020
  • Figure 13-27: Vesanoid - FDA Approval & First Generic Approval Year
  • Figure 13-28: Tretinoin - price for 30 Capsule Supply 7 Price per Unit Capsule (US$), May'2020
  • Figure 13-29: Tretinoin - price for 100 Capsule Supply & Price per Unit Capsule (US$), May'2020
  • Figure 13-30: Tretinoin - Minimum & Maximum Treatment Cost (US$), May'2020
  • Figure 13-31: Clolar - FDA Approval & First Generic Approval Year
  • Figure 13-32: Clolar - Price for 20ml Supply & Price per ml of Intravenous Solution (US$), May'2020
  • Figure 13-33: Generic Clofarabine - Price for 20ml Supply & Price per ml of Intravenous Solution (US$), May'2020
  • Figure 13-34: Clolar - Recommended dose & Dose after Reduction (mg/m2/day)
  • Figure 13-35: Vyxeos - FDA Approval & Patent Expiration Year
  • Figure 13-36: Vyxeos - Price for 1, 2 & 5 Powder for Injection (US$), May'2020
  • Figure 13-37: Vyxeos - Number of Drug Administration Required in Different Treatment Cycles (Dose/Cycle), May'2020
  • Figure 13-38: Sprycel - FDA Approval Year by Tablet Strength
  • Figure 13-39: Sprycel - Patent Issue & Expiration Year
  • Figure 13-40: Sprycel - Price for 60 Tablets & Price per Unit Tablet of 20mg, 50mg and 70mg (US$), May'2020
  • Figure 13-41: Sprycel - Price for 30 Tablets & Price per Unit Tablet of 80mg, 100mg and 140mg (US$), May'2020
  • Figure 13-42: Sprycel - Recommended Dose by Indication (mg/day)
  • Figure 13-43: Sprycel - Recommended Pediatric Dose by Weight (mg/day)
  • Figure 13-44: Iclusig - FDA Approval Year by Tablet Strength (US$), May'2020
  • Figure 13-45: Iclusig - Patent Issue & Expiration Year
  • Figure 13-46: Iclusig - Price for 30 tablets & Price per unit Tablet of 15mg & 45mg (US$), May'2020
  • Figure 13-47: Iclusig - Recommended Initial & Reduced Dose (mg/day)
  • Figure 13-48: Iclusig - Global Sales Value (US$ Million), 2018 & 2019
  • Figure 13-49: Global - Iclusig Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 13-50: Idhifa - Patent Issue & Expiration Year
  • Figure 13-51: Idhifa - Price for 30 Tablets & Price per unit of Oral Tablet (US$), May'2020
  • Figure 13-52: Idhifa - Daily & Full Treatment Cost (US$), May'2020
  • Figure 13-53: Idhifa - Annual Sales Value (US$ Million), 2017 & 2018
  • Figure 13-54: Idhifa - US v/s Rest of World Annual Sales Value (US$ Million), 2019
  • Figure 13-55: Idhifa - US v/s Rest of World Annual Sales Value (%), 2019
  • Figure 13-56: Idhifa - Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 13-57: Tibsovo - FDA Approval Year by Indication
  • Figure 13-58: Tibsovo - Patent Issue & Expiration Year
  • Figure 13-59: Tibsovo - Price for 60 Tablets & Price per unit of 250mg Tablet (US$), May'2020
  • Figure 13-60: Tibsovo - Cost of Daily Treatment & Full Treatment Cost (US$), May'2020
  • Figure 13-61: Global - Tibsovo Sales Value (US$ Million), 2018 & 2019
  • Figure 13-62: Global - Tibsovo Quarterly Sales Value (US$ Million), 2019
  • Figure 13-63: Cladribine - FDA Approval Year by Brand Name
  • Figure 13-64: Mavenclad - Merck's Patent Issue & Expiration Year
  • Figure 13-65: Mavenclad - Ares Trading's Patent Issue & Expiration Year
  • Figure 13-66: Mavenclad - Price for various Tablet Supplies of 10mg (US$), June'2020
  • Figure 13-67: Generic Cladribine - Price for 10 & 1ml Intravenous Solution (US$), June'2020
  • Figure 13-68: Cladribine - Recommended Dose by Route of Administration (mg/Kg/day)
  • Figure 13-69: Purixan - FDA Approval & Exclusivity Expiration Year
  • Figure 13-70: Purixan - Price for 100ml Supply & Price per ml of Oral Suspension (US$), June'2020
  • Figure 13-71: Purixan - Minimum & Maximum Recommended Dose (mg/Kg)
  • Figure 13-72: Xatmep - Patent Issue & Expiration Year
  • Figure 13-73: Xatmep - Price for 60ml Supply & Price per ml of Oral Solution (US$), June'2020
  • Figure 13-74: Xatmep - Price for 100ml Supply & Price per ml of Oral Solution (US$), June'2020
  • Figure 13-75: Xatmep - Cost of Single Treatment Cycle & Annual Treatment Cost (US$), June'2020
  • Figure 13-76: Nipent - FDA Approval & First Generic Approval Year
  • Figure 13-77: Pentostatin - Price for Single Vial of Generic & Branded Pentostatin (US$), May'2020
  • Figure 13-78: Trisenox - FDA Approval Year by Strength
  • Figure 13-79: Trisenox - FDA Approval & First Generic Approval Year
  • Figure 13-80: Arsenic Trioxide - Price for 100ml Supply & Price per ml of Branded & Generic Intravenous Solution of 1mg/ml Dose, May'2020
  • Figure 13-81: Arsenic Trioxide - Price for 60ml Supply & Price per ml of Branded & Generic Intravenous Solution of 2mg/ml Dose (US$), May'2020
  • Figure 13-82: Arsenic Trioxide - Duration of Induction & Consolidation Treatment Cycle (Days)
  • Figure 13-83: Arsenic Trioxide - Number of Required Induction & Consolidation Treatment Cycle
  • Figure 13-84: Vanflyta- Recommended Dose for AML Treatment (mg/day)
  • Figure 13-85: Vanflyta- Recommended Dose & Dose after Reduction (mg/day)
  • Figure 13-86: Ceplene - Europe Market Authorisation & Orphan Designation Year
  • Figure 13-87: Ceplene - Cost of Single Administration, Single Day Treatment & One Treatment Cycle (US$/GBP), June'2020
  • Figure 13-88: Synribo - Patent Issue & Expiration Year
  • Figure 13-89: Synribo - Treatment Phase in Induction & Maintenance Cycle (Weeks/Cycle)
  • Figure 13-90: Supect - Daily, Monthly & Annual Treatment Cost (US$), June'2020
  • Figure 14-1: Iserra - FDA Approval Year by Indication
  • Figure 14-2: Iserra - Patent & Exclusivity Expiration Year
  • Figure 14-3: Iserra - Price for 30 Tablets & Price per unit Tablet (US$), May'2020
  • Figure 14-4: Iserra - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 14-5: Iserra - Annual Sales Value by Region (US$ Million), 2019
  • Figure 14-6: Iserra - Annual Sales Value by Region (%), 2019
  • Figure 14-7: Global - Iserra Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 14-8: Rozlytrek - FDA Approval & Patent Expiration Year
  • Figure 14-9: Rozyltrek - Price for 30 Capsules Supply & Price per unit of 100 mg Oral Tablet (US$), April'2020
  • Figure 14-10: Rozyltrek - Price for 90 Capsules Supply & Price per unit of 200 mg Oral Tablet (US$), April'2020
  • Figure 14-11: Rozyltrek - Pediatric Dose by Surface Area (mg), April'2020
  • Figure 14-12: Tagrisso - Patent Issue & Expiration Year
  • Figure 14-13: Tagrisso - Price for 30 Tablet Supply & Price per unit of 200 mg Oral Tablet (US$), April'2020
  • Figure 14-14: Tagrisso - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 14-15: Tagrisso - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 14-16: Tagrisso - Annual Sales Value by Region (US$ Million), 2019
  • Figure 14-17: Tagrisso - Annual Sales Value by Region (%), 2019
  • Figure 14-18: Global - Tagrisso Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 14-19: Tarceva - FDA Approval & First Generic Approval Year
  • Figure 14-20: Tarceva - Price for Supply of 30 Tablets & Price per unit Tablet of Various Dose Regimens (US$), May'2020
  • Figure 14-21: Generic Erlotinib - Average Price for Supply of 30 Tablets & Price for 20 Tablets of various Doses (US$), May'2020
  • Figure 14-22: Tarceva - Recommended dose by Indication (mg/day)
  • Figure 14-23: Alunbirg - Patent Issue & Expiration Year
  • Figure 14-24: Alunbirg - Price for 30 Tablets of Various Dose Regimens (US$), June'2020
  • Figure 14-25: Alunbirg - Recommended & Reduced Dose (mg)
  • Figure 14-26: Lorbrena - FDA Approval & Patent expiration Years
  • Figure 14-27: Lorbrena - Price for 30 Tablet Supply & Price per unit of 25mg Oral Tablet (US$), April'2020
  • Figure 14-28: Lorbrena - Price for 30 Tablet Supply & Price per unit of 100 mg Oral Tablet (US$), April'2020
  • Figure 14-29: Lorbrena - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 14-30: Navelbine - FDA Approval & First Generic Approval Year
  • Figure 14-31: Navelbine - Price for 1ml & 5ml Supply of Intravenous Solution (US$), May'2020
  • Figure 14-32: Generic Venorelbine - Price for 1ml & 5ml Supply of Intravenous Solution (US$), May'2020
  • Figure 14-33: Zykadia - FDA Approval by Indication
  • Figure 14-34: Zykadia - Patent Expiration Year by Assignee
  • Figure 14-35: Zykadia - Price for 84 Capsules Supply & Price per unit of Oral Capsule (US$), April'2020
  • Figure 14-36: Zykadia - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 14-37: Alimta - FDA Approval Year by Dose Regimen
  • Figure 14-38: Alimta - Patent Issue & Expiration Year
  • Figure 14-39: Alimta - Price for 100mg & 500mg Intravenous Powder (US$), April'2020
  • Figure 14-40: Alimta - Treatment Cycle required in Combination with Pembrolizumab v/s Cisplatin, April'2020
  • Figure 14-41: Alimta - Cost of Single Treatment Cycle & Full Treatment Cost of NSCLC (US$), April'2020
  • Figure 14-42: Alimta - Annual Sales Value (US$ Billion), 2016 - 2019
  • Figure 14-43: Alimta - US v/s Rest of World Annual Sales Value (US$ Million), 2019
  • Figure 14-44: Alimta - US v/s Rest of World Annual Sales Value (%), 2019
  • Figure 14-45: Alimta - Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 14-46: Alimta - US Quarterly Sales Value (US$ Million), 2019
  • Figure 14-47: Alecensa - FDA Approval by Indication
  • Figure 14-48: Alecensa - Patent Issue & expiration Year
  • Figure 14-49: Alecensa - Price for 240 Tablet Supply & Price per unit of Oral Tablet (US$), April'2020
  • Figure 14-50: Alecensa - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April'2020
  • Figure 14-51: Xalkori - Patent Issue & Expiration Year
  • Figure 14-52: Xalkori - Price for 60 Capsule Supply & Price per unit of Oral Capsule (US$), April'2020
  • Figure 14-53: Xalkori - Recommended & Reduced Daily Dose (mg)
  • Figure 14-54: Ofev - Patent Issue & Expiration Year
  • Figure 14-55: Ofev - Price for 60 Capsule & Price per unit Capsule (US$), June'2020
  • Figure 14-56: Ofev - Recommended & Reduced Dose (mg/Twice Daily)
  • Figure 14-57: Global - Ofev Sales Value (EUR/US$), 2017 - 2019
  • Figure 14-58: Focus V - Recommended & Reduced Dose (Mcg)
  • Figure 14-59: Focus V - Duration of Treatment Phase & Rest Phase in One Cycle (Days)
  • Figure 14-60: Conmana - Price for 21 Tablets & Price Per unit Tablet (CNY/US$), June'2020
  • Figure 15-1: Aliqopa - Patent Issue & Expiration Year
  • Figure 15-2: Aliqopa - Cost of Single Treatment Cycle & Annual Treatment Cost (US$), May'2020
  • Figure 15-3: Uvadex - Price for 120 ml Supply & Price per unit ml of Intravenous Solution (US$), June'2020
  • Figure 15-4: Uvadex - Duration of Single Treatment Cycle & Full Treatment (Weeks)
  • Figure 15-5: Folotyn - Patent Issue & Expiration Year
  • Figure 15-6: Folotyn - Price for Supply of 1ml & 2ml Intravenous Solution of 20mg/ml Dose (US$), June'2020
  • Figure 15-7: Folotyn - Recommended Initial & Reduced Dose (mg/m2)
  • Figure 15-8: Bexarotene Topical - FDA Approval & Patent Expiration Year
  • Figure 15-9: Targretin Gel - Price for 60gm gel & Price per gram of 1% Gel (US$), May'2020
  • Figure 15-10: Pixantrone - Duration of Single Treatment Cycle & Full Treatment (Weeks)
  • Figure 15-11: Pixuvri - Cost of Single Administration, One Treatment Cycle & Full Treatment (US$/GBP), June'2020
  • Figure 15-12: Beledaq - Patent Issue & Expiration Year
  • Figure 15-13: Beledaq - Cost of Single Administration & cost of Single Treatment Cycle (US$), May'2020
  • Figure 15-14: Brukinsa - Patent Issue & Expiration Year
  • Figure 15-15: Brukinsa - Price for Supply of 120 tablets & Price Per unit Tablet (US$), May'2020
  • Figure 15-16: Brukinsa - Recommended Dose & Dose after Reduction (mg/day)
  • Figure 15-17: Zolinza - FDA Approval & Patent Expiration Year
  • Figure 15-18: Zolinza - Price for Supply of 120 tablets & Price Per unit Tablet (US$), May'2020
  • Figure 15-19: Zolinza - Recommended Dose & Dose after Reduction (mg/day)
  • Figure 15-20: Romidepsin - FDA Approval Year by Indication
  • Figure 15-21: Romidepsin - Price for a Supply of 10mg branded & generic Intravenous Powder (US$), May'2020
  • Figure 15-22: Istodax - Cost of Single Dose & Single Treatment cycle (US$), May'2020
  • Figure 15-23: Tragretin - FDA Approval & First Generic Approval Year
  • Figure 15-24: Targetrin - Price for 100 Capsule Supply & Price per unit Capsules (US$), May'2020
  • Figure 15-25: Generic bexarotene - Price for Capsule Supply & Price per unit Capsules (US$), May'2020
  • Figure 15-26: Bexarotene - Daily Treatment Cost using Branded v/s Generic (US$), May'2020
  • Figure 15-27: Valchlor - Number of Patents by Assignee
  • Figure 15-28: Valchlor - Patent Expiration Year by Asignee
  • Figure 15-29: Valchlor - Price for 60gm Gel & Price per Gram of 0.016% Gel (US$), May'2020
  • Figure 16-1: Ninlaro - Number of Patents by Assignee Name
  • Figure 16-2: Ninlaro - Patent Expiration by Assignee Name
  • Figure 16-3: Ninlaro - Price for 30 Capsules & price per unit Capsules of Various Dose Regimen (US$), May'2020
  • Figure 16-4: Ninlaro - Recommended Dose & Reduced Dose (mg/week for 3weeks/Cycle)
  • Figure 16-5: Evomela - Patent Issue & Expiration Year
  • Figure 16-6: Evomela - Duration of Single Treatment Cycle & Full Palliative Treatment (Weeks)
  • Figure 16-7: Evomela - Cost of Single Treatment Cycle & Full Palliative Treatment (US$) June'2020
  • Figure 16-8: Thalomid - FDA Approval Year by Capsule Strength
  • Figure 16-9: Thalomid - Patent Issue & Expiration Year
  • Figure 16-10: Thalomid - Price for 10 & 280 Capsules of 50mg Dose (US$), June'2020
  • Figure 16-11: Thalomid - Price for 140 Capsules & Price per unit Capsules of 100mg Dose (US$), June'2020
  • Figure 16-12: Thalomid - Price for 112 Capsules & Price per unit Capsules of 150mg Dose (US$), June'2020
  • Figure 16-13: Thalomid - Price for 84 Capsules & Price per unit Capsules of 200mg Dose (US$), June'2020
  • Figure 16-14: Xpovio - FDA Approval & Patent Expiration Year
  • Figure 16-15: Xpovio - Price for 12 Tablet Supply & Price per unit Tablet of 20mg Tablet (US$), May'2020
  • Figure 16-16: Xpovio - Quarterly Sales Value (US$ Million), May'2020
  • Figure 16-17: Farydak - Patent Issue & Expiration Year
  • Figure 16-18: Farydak - Price for 30 Tablet Supply & Price per unit Tablet (US$), May'2020
  • Figure 16-19: Farydak - Number of Treatment Cycle required by Type of Therapy, May'2020
  • Figure 16-20: Velcade - FDA Approval Year by Indication
  • Figure 16-21: Velcade - Patent Issue & Expiration Year
  • Figure 16-22: Bortezomib - Generic Approval By Companies
  • Figure 16-23: Global - Velcade Sales Value (US$ Million), 2017 & 2018
  • Figure 16-24: Pomalyst - FDA Approval & Patent Expiration Year
  • Figure 16-25: Pomalyst - Price for 21 Capsules Supply & Price per unit Capsule of Various Dose Regimens (US$), May'2020
  • Figure 16-26: Pomalyst - Price for 100 Capsules Supply & Price per unit Capsule of Various Dose Regimens (US$), May'2020
  • Figure 16-27: Pomalyst - Recommended Initial & Reduced Dose (mg/day)
  • Figure 16-28: Global - Pomalyst Sales Value (US$ Million), 2017 - 2019
  • Figure 16-29: Pomalyst - US v/s Rest of World Annual Sales Value (US$ Million), 2018
  • Figure 16-30: Pomalyst - US v/s Rest of World Annual Sales Value (%), 2018
  • Figure 16-31: Pomalyst - Quarterly Sales Value (US$ Million), 2019
  • Figure 16-32: Neofordex - Price for 10 Tablets & Price per unit Tablet (GBP/US$), June'2020
  • Figure 17-1: Xtandi - FDA Approval Year by Indication
  • Figure 17-2: Xtandi - Patent Issue & Expiration Year
  • Figure 17-3: Xtandi - Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), May'2020
  • Figure 17-4: Xtandi - Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April'2020
  • Figure 17-5: Xtandi - Cost of Single Capsule & Daily Treatment Cost (US$), April'2020
  • Figure 17-6: Erleada - Aragon related Patent Issue & expiration Year
  • Figure 17-7: Erleada - University of California related Patent Issue & expiration Year
  • Figure 17-8: Erleada - Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), April'2020
  • Figure 17-9: Erleada - Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April'2020
  • Figure 17-10: Balversa - Patent Issue & Expiration year
  • Figure 17-11: Balversa - Price for 56 & 84 Tablet Supplies of 3mg (US$), May'2020
  • Figure 17-12: Balversa - Price for 28 & 56 Tablet Supplies of 4mg (US$), May'2020
  • Figure 17-13: Balversa - Price for 28 Tablets & Price Per unit Tablet (US$), May'2020
  • Figure 17-14: Balversa - Initial & Increased Dose for Prostate Cancer (mg/day), May'2020
  • Figure 17-15: Balversa - Recommended Dose after Reduction for Prostate Cancer (mg/day), May'2020
  • Figure 17-16: Nubeqa - Aragon Related Patent Issue & Expiration Year
  • Figure 17-17: Nubeqa - Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), April'2020
  • Figure 17-18: Nubeqa - Price of Single Tablet & Daily Treatment Cost (US$), April'2020
  • Figure 17-19: Casodex - FDA Approval & Patent Expiration Year
  • Figure 17-20: Casodax - Price for 30 Tablets Supply & Price per unit Tablet (US$), May'2020
  • Figure 17-21: Generic Bicalutamide - Price for 30 Tablets Supply & Price per unit Tablet (US$), May'2020
  • Figure 17-22: Nilandrone - FDA Approval & First Generic Approval Year
  • Figure 17-23: Eloxatin - FDA Approval Year by Strength of Tablet
  • Figure 17-24: Nilandrone - Price for 30 Tablet Supply & Price per unit tablet of 150mg (US$), May'2020
  • Figure 17-25: Nilandrone - Recommended Dose for Prostate Cancer Treatment (mg/day), May'2020
  • Figure 17-26: Zytiga - FDA Approval by Indication
  • Figure 17-27: Zytiga - FDA approval & First generic Approval Year
  • Figure 17-28: Zytiga - Price for Supply of 120 tablets & Price Per unit Tablet of 250mg (US$), May'2020
  • Figure 17-29: Zytiga - Price for Supply of 60 tablets & Price Per unit Tablet of 500mg (US$), May'2020
  • Figure 17-30: Generic Abiraterone - Price for Supply of 30 Tablets & 120 tablets & Price Per unit Tablet of 250mg (US$), May'2020
  • Figure 17-31: Abiraterone - Daily Treatment Cost Branded v/s Generic (US$), May'2020
  • Figure 17-32: Xofigo - Patent Issue & expiration Year
  • Figure 17-33: Xofigo - Duration of One Treatment Cycle & Full Treatment Duration for Prostate Cancer (Weeks), April'2020
  • Figure 17-34: Tookad - Price for 183mg Supply & Cost of Treatment (GBP/US$), June'2020
  • Figure 18-1: Ayvatik - Patent Issue & Expiration Year
  • Figure 18-2: Verzenio - Price for a Supply of 30 Tablets & Price per unit Tablet (US$), May'2020
  • Figure 18-3: Ayvakit - Initial & Reduced Dose (mg), May'2020
  • Figure 18-4: Focus V - Recommended Initial & Reduced Dose (mg/day)
  • Figure 18-5: Teysuno - Approval Year in Europe & Japan
  • Figure 18-6: Teysuno - Price for 84 Capsules & Price per unit Capsule (INR/US$), June'2020
  • Figure 18-7: TS1- Price for 56 Capsules & Price per unit Capsule (US$), June'2020
  • Figure 18-8: Teysuno - Recommended & Reduced Dose (mg/m2 Twice Daily)
  • Figure 18-9: Eptaplatin - Min8imum & MaximumRecommended Dose (mg/m2), June'2020
  • Figure 19-1: Axumin - Number of Patents by Assignee
  • Figure 19-2: Axumin - Patent Expiration Year by Assignee
  • Figure 19-3: Lymphoseek - FDA Approval Year by Indication
  • Figure 19-4: Lymphoseek - Patent Issue & Expiration Year
  • Figure 19-5: Sonazoid - PMDA Approval Year by Indication
  • Figure 19-6: Cysview - Patent Issue & Expiration Year
  • Figure 19-7: Gadavist - FDA Approval Year by Supply
  • Figure 19-8: Gadavist - Patent Issue & Expiration Year
  • Figure 19-9: Gadavist - Price for Various Supplies of Intravenous Solution (US$), June'2020
  • Figure 20-1: Mektovi - Number of Patents by Asignee
  • Figure 20-2: Mektovi - Patent Expiration Year by Assignee
  • Figure 20-3: Mektovi - Price for 180 Tablet Supply & Price per unit Tablet (US$), May'2020
  • Figure 20-4: Mektovi - Recommended & Reduced Dose (mg/twice daily), May'2020
  • Figure 20-5: Cotellic - Number of Patents by Assignee
  • Figure 20-6: Cotellic - Patent Expiration Year by Asignee
  • Figure 20-7: Cotellic - Price for 63 Tablets Supply & Price per unit Tablet (US$), May'2020
  • Figure 20-8: Cotellic - Recommended & Reduced Dose (mg/day)
  • Figure 20-9: Odomzo - Novartis Patent Issue & Expiration Year
  • Figure 20-10: Odomzo - IRM's Patent Issue & Expiration Year
  • Figure 20-11: Odomzo - Price for 30 Capsules & price per unit Capsules of 200mg (US$), May'2020
  • Figure 20-12: Erivedge - Patent Issue & Expiration Year
  • Figure 20-13: Erivedge - Price for 28 Capsules & Price per unit of 150mg Capsule (US$), May'2020
  • Figure 20-14: Imiquimod - FDA Approval Year by Brand Name
  • Figure 20-15: Aldara - Patent Issue & Expiration Year
  • Figure 20-16: Aldara - Price for 12 Cream Supply & Price per unit 5% Cream (US$), June'2020
  • Figure 20-17: Zyclara - Price for 7.5gm Supply & Price per unit of 2.5% Cream (US$), June'2020
  • Figure 20-18: Zyclara - Price for 7.5gm Supply & Price per unit of 3.75% Cream (US$), June'2020
  • Figure 20-19: Zyclara - Price for 28gm Supply & Price per unit of 3.75% Cream (US$), June'2020
  • Figure 20-20: Generic Imiquimod - Price for 7.5gm Supply & Price per unit of 3.75% Cream (US$), June'2020
  • Figure 20-21: Generic Imiquimod - Price for Supply of 12 & 24 Creams of 5% Concentration (US$), June'2020
  • Figure 20-22: Imiquimod - Treatment Duration by Indication (Weeks)
  • Figure 20-23: Ameluz - FDA Approval & Patent Expiration Year
  • Figure 20-24: Ameluz - Price for 2gm Supply & Price per unit of 10% Cream (US$), May'2020
  • Figure 20-25: Gliolan - Price for 10 Vials & Price per unit Vial of 1.5gm Powder for Injection (US$), May'2020
  • Figure 20-26: Methyl Aminolevulinate - FDA Approval Year by Indication
  • Figure 20-27: Metvix PDT - Minimum & Maximum Cost of Treatment (US$/CND), June'2020
  • Figure 20-28: Zelboraf - Plexxikon's Patent Issue & Expiration Year
  • Figure 20-29: Zelboraf - Roche's Patent Issue & Expiration Year
  • Figure 20-30: Zelboraf - Price for 112 Tablets & Price per unit Tablet (US$), May'2020
  • Figure 21-1: Onivyde - FDA Approval & Patent Expiration Year
  • Figure 21-2: Onivyde - Cost of 10 ml Supply & Price per ml of Intravenous Dispersion (US$), May'2020
  • Figure 21-3: Onivyde - Cost of Single Treatment Cycle & Annual Treatment Cost (US$), May'2020
  • Figure 21-4: Global - Onivyde Annual Sales Value (US$/EUR Million), 2017 - 2019
  • Figure 21-5: Global - Onivyde Quarterly Sales Value (US$/EUR Million), 2019
  • Figure 21-6: Global - Onivyde Quarterly Sales Value (US$/EUR Million), 2018
  • Figure 22-1: Caprelsa - Patent Issue & Expiration Year
  • Figure 22-2: Caprelsa - Price for 30 Tablets & Price per unit of 100mg Tablet (US$), May'2020
  • Figure 22-3: Caprelsa - Price for 30 Tablets & Price per unit of 300mg Tablet (US$), May'2020
  • Figure 22-4: Caprelsa - Recommended Initial & Reduced Dose (mg/daily)
  • Figure 23-1: Inflyta - FDA Approval by Type of Therapy
  • Figure 23-2: Inflyta - Patent Issue & Expiration Year
  • Figure 23-3: Inlyta - Price for 180 Capsule Supply & Price per unit Capsules of 1mg (US$), May'2020
  • Figure 23-4: Inlyta - Price for 60 Capsule Supply & Price per unit Capsules of 5mg (US$), May'2020
  • Figure 24-1: Lonsurf - FDA Approval & Patent Expiration Year
  • Figure 24-2: Lonsurf - Price for various Supplies of 6.14mg-15mg Tablet (US$), April'2020
  • Figure 24-3: Lonsurf - Price for Various Supplies of 8.19mg-20mg Tablet (US$), April'2020
  • Figure 24-4: Lonsurf - Recommended Dose by Surface Area (mg per day)
  • Figure 24-5: Camptosar - FDA Approval & First Generic Approval Year
  • Figure 24-6: Camptosar - FDA Approval Year by Strength of Intravenous Solution
  • Figure 24-7: Camptosar - Price for Various Supplies of 20mg/ml Intravenous Solution (US$), May'2020
  • Figure 24-8: Generic Irinotecan - Average Price for Various Supplies of 60mg Tablet (US$), May'2020
  • Figure 24-9: Camptosar Monotherapy - Treatment Phase & Rest Phase in 125mg/ m2 Dose (Week), May'2020
  • Figure 24-10: Eloxatin - FDA Approval & First Generic Approval Year
  • Figure 24-11: Eloxatin - FDA Approval Year by Strength of Intravenous Solution
  • Figure 24-12: Eloxatin - Price for 10ml & 20ml Intravenous Solution (US$), May'2020
  • Figure 24-13: Generic Oxaliplatin - Price for various supplies of Intravenous Solution (US$), May'2020
  • Figure 24-14: Eloxatin - Duration of Single Treatment Cycle & Full Treatment (Weeks), May'2020
  • Figure 24-15: Eloxatin - Recommended & Reduced Dose (mg/m2 weeks), May'2020
  • Figure 24-16: Raltitrexed - Recommended Initial & Reduced Dose (mg/m2/2 weeks)
  • Figure 24-17: Raltitrexed - Cost of Single Treatment Cycle & Full Treatment
  • Figure 24-18: Fruquintinib - Duration of Treatment Phase & Rest Phase in Single Treatment Cycle (Days)
  • Figure 25-1: Viktravi - Number of Patents by Assignee Name
  • Figure 25-2: Viktravi - Patents Expiration Year by Assignee Name
  • Figure 25-3: Vitraki - Price for 60 Capsules Supply of 25mg & 100mg Dose (US$), May'2020
  • Figure 25-4: Vitraki - Price for 100 ml Supply & Price per ml of Oral Solution (US$), May'2020
  • Figure 25-5: Vitraki - Recommended & Reduced Adult Dose (mg Twice Daily), May'2020
  • Figure 25-6: Vitraki - Recommended & Reduced Pediatric Dose (mg/m2 Twice Daily), May'2020
  • Figure 26-1: Fludarabin - FDA Approval Year by Brand Name
  • Figure 26-2: Fludarabin - Price for 50mg Intravenous Powder & 2 ml Intravenous Solution for Injection (US$), May'2020
  • Figure 26-3: Gemzar - FDA Approval & First Generic Approval Year
  • Figure 26-4: Gemzar - Price for the Supply of 1 Gram & 200mg Powder for Injection (US$), May'2020
  • Figure 26-5: Gemzar - Cost of Single Treatment Cycle & Cost of Single Administration (US$), May'2020
  • Figure 26-6: Nexavar - FDA Approval Year by Indication
  • Figure 26-7: Nexavar - Price for a supply of 120 Tablets & Price per unit Tablet (US$), May'2020
  • Figure 26-8: Nexavar - Daily, Monthly & Annual Treatment Cost (US$), May'2020
  • Figure 26-9: Nexavar - Global Sales Value (US$ Million), 2018 & 2019
  • Figure 26-10: Global - Nexavar Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 26-11: Rubraca - FDA Approval Year by Indication
  • Figure 26-12: Rubraca - FDA Approval Year by Strength
  • Figure 26-13: Rubraca - Number of Patents by Assignee
  • Figure 26-14: Rubraca - Patents Expiration Year by Assignee
  • Figure 26-15: Rubraca - Price for a Supply of 60 Tablets & Price per unit Tablet (US$), May'2020
  • Figure 26-16: Rubraca - Recommended Initial & Reduced Dose (mg/twice daily)
  • Figure 26-17: Rubraca - Global Sales Value (US$ Million), 2018 & 2019
  • Figure 26-18: Global - Rubraca Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 26-19: Aridamycin - Price for 10mg & 50mg Powder for Injection (US$), May'2020
  • Figure 26-20: Aridamycin - Price for Various Supplies of Solution for Injection (US$), May'2020
  • Figure 26-21: Generic Doxorubicin - Price for Various Supplies of Solution for Injection (US$), May'2020
  • Figure 26-22: Aridamycin Monotherapy - Minimum & Maximum Dose (mg/m2 once every 3 Weeks)
  • Figure 26-23: Aridamycin Combinational - Minimum & Maximum Dose (mg/m2 once every 3 Weeks)
  • Figure 26-24: Calquence - FDA Approval Year by Indication
  • Figure 26-25: Calquence - Number of Patents by Assignee
  • Figure 26-26: Calquence - Patent Expiration Year by Assignee
  • Figure 26-27: Calquence - Price for 60 capsules & Price Per unit Capsule (US$), May'2020
  • Figure 26-28: Calquence - Recommended dose by Type of Therapy (mg/day), May'2020
  • Figure 26-29: Calquence - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 26-30: Calquence - Annual Sales Value by Region (US$ Million), 2019
  • Figure 26-31: Calquence - Annual Sales Value by Region (%), 2019
  • Figure 26-32: Global - Calquence Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 26-33: Ibrutinib - FDA Approval Year by Indication
  • Figure 26-34: Ibrutinib - FDA Approval Year by Dosage Form
  • Figure 26-35: Imbruvica - Price for 90 & 120 Capsule Supplies of 140mg (US$), May'2020
  • Figure 26-36: Imbruvica Capsule - Price for 28 Capsule & Price Per unit Capsule of 70mg (US$), May'2020
  • Figure 26-37: Imbruvica Tablet - Price for 28 Tablets & Price Per unit Tablet of Various Doses (US$), May'2020
  • Figure 26-38: Imbruvica - Recommended Daily Dose by Indication (mg), May'2020
  • Figure 26-39: Imbruvica - Annual Sales Value (US$ Billion), 2017 - 2019
  • Figure 26-40: Imbruvica - Annual Sales Value by Region (US$ Million), 2019
  • Figure 26-41: Imbruvica - Annual Sales Value by Region (%), 2019
  • Figure 26-42: Global - Imbruvica Quarterly Sales Value (US$ Million), 2019
  • Figure 26-43: Vidaza - FDA & First generic Approval Year
  • Figure 26-44: Vidaza - Branded v/s Generic Price for 100mg Intravenous powder (US$), May'2020
  • Figure 26-45: Vidaza - Dose for Initial & Subsequent Treatment Cycle (mg/m2)
  • Figure 26-46: Vidaza - Cost of Initial & Subsequent Treatment Cycle (US$), May'2020
  • Figure 26-47: Revlimid - FDA Approval Year by Indication
  • Figure 26-48: Revlimid - FDA Approval & Patent Expiration Year
  • Figure 26-49: Revlimid - Price for 28 capsules & 100 Capsules of 2.5mg, 5mg & 10mg Capsules (US$), May'2020
  • Figure 26-50: Revlimid - Price for 21 capsules & 100 Capsules of 15mg, 20mg & 25mg Capsules (US$), May'2020
  • Figure 26-51: Revlimid - Recommended Daily Dose by Indications (mg)
  • Figure 26-52: Global - Revlimid Sales Value (US$ Million), 2017 - 2019
  • Figure 26-53: Global - Revlimid Quarterly Sales Value (US$ Million), 2019
  • Figure 26-54: Doxil - FDA Approval & First Generic Approval Year
  • Figure 26-55: Doxil - Price for Supply of 10 ml & Price per ml of Intravenous Solution (US$), April'2020
  • Figure 26-56: Doxil - Price for Supply of 25 ml & Price per ml of Intravenous Solution (US$), April'2020
  • Figure 26-57: Lipodox - Price for Supply of 10 ml & Price per ml of Intravenous Solution (US$), April'2020
  • Figure 26-58: Lipodox 50 - Price for Supply of 25 ml & Price per ml of Intravenous Solution (US$), April'2020
  • Figure 26-59: Doxil - Recommended Single Dose by Indication (mg/m2), April'2020
  • Figure 26-60: Doxil - Duration of Single Treatment Cycle (Week), April'2020
  • Figure 26-61: Doxil - Cost of Single Treatment Cycle & Annual Treatment Cost of Ovarian Cancer (US$), April'2020
  • Figure 26-62: Doxil - Cost of Single Treatment Cycle & Annual Treatment Cost of Kaposi's sarcoma (US$), April'2020
  • Figure 26-63: Tazverik - FDA Approval & Patent Expiration Year
  • Figure 26-64: Tazverik - Price for 240 Tablets & price per unit Tablet (US$), May'2020
  • Figure 26-65: Tazverik - Recommended Dose & Dose after Reduction (mg Twice Daily), May'2020
  • Figure 26-66: Busulfan - FDA Approval & First Generic Approval Year
  • Figure 26-67: Busulfex - Price for 80ml Supply & Price per ml of Intravenous Solution (US$), May'2020
  • Figure 26-68: Busulfex - Cost of Single Administration, Single Day & Full Treatment Cost (US$), May'2020
  • Figure 26-69: Gilotrif - FDA Approval Year by Indication
  • Figure 26-70: Gilotrif - Patent Issue & Expiration Year
  • Figure 26-71: Gilotrif - Price for 30 Tablet Supply & Price per unit of Oral Tablet (US$), June'2020
  • Figure 26-72: Gilotrif - Recommended & Reduced Dose for NSCLC Treatment (mg per day), June'2020
  • Figure 26-73: Infugem - Patent Issue & Expiration Year
  • Figure 26-74: Infugem - Price for Supply of 120ml & Price per ml of 10ml/ml Intravenous Solution (US$), June'2020
  • Figure 26-75: Infugem - Price for Supply of 240ml & Price per ml of 10ml/ml Intravenous Solution (US$), June'2020
  • Figure 26-76: Gliadel - FDA Approval & Patent Expiration Year
  • Figure 26-77: Gliadel - Price for 8 Implanted Devices & Price per unit Tablet (US$), May'2020
  • Figure 26-78: Halaven - FDA Approval Year by Indication
  • Figure 26-79: Halaven - Patent Issue & Expiration Year
  • Figure 26-80: Halaven - Price for 2ml Supply & Price per ml of Intravenous Solution (US$), May'2020
  • Figure 26-81: Halaven - Recommended & Reduced Dose (mg/m2twice daily), May'2020
  • Figure 26-82: Abraxane - FDA Approval Year by Indication
  • Figure 26-83: Abraxane - US & Europe Patent Expiration Year
  • Figure 26-84: Abraxane - Recommended Single Dose by Indication (mg/m2), April'2020
  • Figure 26-85: Abraxane - Duration of Single Treatment Cycle (Week), April'2020
  • Figure 26-86: Abraxane - Cost of Single Treatment Cycle & Annual Treatment Cost of Breast Cancer (US$), April'2020
  • Figure 26-87: Abraxane - Cost of Single Treatment Cycle & Annual Treatment Cost of NSCLC (US$), April'2020
  • Figure 26-88: Abraxane - Cost of Single Treatment Cycle & Annual Treatment Cost of Pancreatic Cancer (US$), April'2020
  • Figure 26-89: Abraxane - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 26-90: Abraxane - US v/s Rest of World Annual Sales Value (US$ Million), 2019
  • Figure 26-91: Abraxane - US v/s Rest of World Annual Sales Value (US$ Million), 2019
  • Figure 26-92: Abraxane - Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 26-93: Abraxane - US Quarterly Sales Value (US$ Million), 2019
  • Figure 26-94: Yondelis - Patent Issue & Expiration Year
  • Figure 26-95: Yondelis - Recommended & Reduced Dose (mg/m2/3weeks)
  • Figure 26-96: Global - Yondelis Annual Sales Value (US$/EUR Million), 2017 - 2019
  • Figure 26-97: Global - Yondelis Quarterly Sales Value (US$/EUR Million), 2019
  • Figure 26-98: Taxol - FDA Approval & First Generic Approval Year
  • Figure 26-99: Paclitaxel - Average Price for Various Supplies of 6mg/ml Intravenous Solution (US$), May'2020
  • Figure 26-100: Paclitaxel - Recommended Dose by Cancer Type (mg/m2/3weeks)
  • Figure 26-101: Taxotere - FDA Approval year by Strength
  • Figure 26-102: Taxotere - First Generic Approval year by Strength
  • Figure 26-103: Docetaxel - FDA Approval year by Companies
  • Figure 26-104: Taxotere - Price for 4ml Supply & Price per ml of 20mg/ml Intravenous Solution (US$, May'2020
  • Figure 26-105: Docetaxel - Average Price for 2ml, 8ml & 16ml Supply 10mg/ml Intravenous Solution (US$, May'2020
  • Figure 26-106: Docetaxel - Average Price for 1ml, 4ml, 8ml & 10ml Supply 20mg/ml Intravenous Solution (US$, May'2020
  • Figure 26-107: Docetaxel - Minimum & Maximum Dose for breast Cancer Management (mg/m2/3 weeks)
  • Figure 26-108: Zydelig - Number of Patents by Asignee
  • Figure 26-109: Zydelig - Patent Expiration Year by Asignee
  • Figure 26-110: Zydelig - Price for 60 Tablet Supply & Price per Unit Tablet (US$), May'2020
  • Figure 26-111: Zydelig - Recommended & Reduced Dose (mg/day)
  • Figure 26-112: Global - Zydelig Sales Value (US$ Million), 2017 - 2019
  • Figure 26-113: Zydelig - Annual Sales Value by Region (US$ Million), 2019
  • Figure 26-114: Zydelig - Annual Sales Value by Region (%), 2019
  • Figure 26-115: Zydelig - Quarterly Sales Value (US$ Million), 2018 - 2019
  • Figure 26-116: Copiktra - Interllikine's Patent Issue & Expiration Year
  • Figure 26-117: Copiktra - Infinity Pharma's Patent Issue & Expiration Year
  • Figure 26-118: Copiktra - Price for 56 Capsules Supply & Price per unit Capsule (US$), May'2020
  • Figure 26-119: Copiktra - Recommended & Reduced Dose (mg/day)
  • Figure 26-120: Stivarga - FDA Approval Year by Indication
  • Figure 26-121: Stivarga - Patent Issue & Expiration Year
  • Figure 26-122: Stivarga - Price for 84 Tablets Supply & Price per unit Tablet (US$), May'2020
  • Figure 26-123: Stivarga - Recommended & Reduced Dose (mg/day)
  • Figure 26-124: Arranon - FDA Approval Year & Patent Expiration Year
  • Figure 26-125: Arranon - Price for 50ml & 300ml intravenous Solution of 5mg/ml Dose (US$), May'2020
  • Figure 26-126: Arranon - Adult & Pediatric Dose (mg/m2)
  • Figure 26-127: Xeloda - FDA Approval Year & First Generic Approval Year
  • Figure 26-128: Capecitabine - Price for 60 Tablet Supply & Price per unit of 150mg Branded & Generic tablet (US$), May'2020
  • Figure 26-129: Xeloda - Price for 120 Tablet Supply & Price per unit of 500mg tablet (US$), May'2020
  • Figure 26-130: Capecitabine - Price for 120 Tablet Supply & Price per unit of 500mg tablet (US$), May'2020
  • Figure 26-131: Capecitabine - Duration of Single Treatment Cycle & Full Treatment (Weeks)
  • Figure 26-132: Lenvima - FDA Approval Year by Indication
  • Figure 26-133: Lenvima - Patent & Exclusivity Expiration Year
  • Figure 26-134: Lenvima - Price for 30 Capsules & Price per unit Capsules of 4mg & 10mg (US$), May'2020
  • Figure 26-135: Lenvima - Price for 60 Capsules & Price per unit Capsules 8mg, 14mg & 20mg (US$), May'2020
  • Figure 26-136: Lenvima - Price for 90 Capsules & Price per unit Capsules (US$), May'2020
  • Figure 26-137: Lenvima - Dose by Cancer Type (mg/day), May'2020
  • Figure 26-138: Lenvima - Dose for Hepatocellular Carcinoma by Weight (mg/day), May'2020
  • Figure 26-139: Lenvima - Annual Sales Value (US$ Million), 2018 & 2019
  • Figure 26-140: Global - Lenvima Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 26-141: Lynparza - FDA Approval Year by Indication
  • Figure 26-142: Lynparza - Number of Patent Issued by Assignee Name
  • Figure 26-143: Lynparza - Patent Expiration Year by Assignee
  • Figure 26-144: Lynparza - Price for 60 & 120 Tablet Supply & Price per Unit Tablet (US$), May'2020
  • Figure 26-145: Lynparza - Recommended Dose & Dose after Reduction (mg/day)
  • Figure 26-146: Lynparza - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 26-147: Lynparza - Annual Sales Value by Region (US$ Million), 2019
  • Figure 26-148: Lynparza - Annual Sales Value by Region (%), 2019
  • Figure 26-149: Global - Lynparza Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 26-150: Tasigna - Patent Issue & Expiration Year
  • Figure 26-151: Zejula - Price for 30 capsules Supply & Price per unit of Oral capsule (US$), April'2020
  • Figure 26-152: Zejula - Price for 90 capsules Supply & Price per unit of Oral capsule (US$), April'2020
  • Figure 26-153: Zejula - Recommended Dose & Dose after Reduction (mg/day), April'2020
  • Figure 26-154: Zejula - Annual Sales Value (US$/GBP Million), 2017 - 2019
  • Figure 26-155: Zejula - Annual Sales Value by Region (US$/GBP Million), 2019
  • Figure 26-156: Zejula - Annual Sales Value by Region (%), 2019
  • Figure 26-157: Global - Zejula Quarterly Sales Value (US$ Million), 2019
  • Figure 26-158: Votrient - FDA Approval Year by indication
  • Figure 26-159: Votrient - Patent Issue & Expiration Year
  • Figure 26-160: Votrient - Price for 120 Tablets Supply & Price per unit Tablet (US$), May'2020
  • Figure 26-161: Global - Votrient Sales Value (US$ Million), 2017 - 2019
  • Figure 26-162: Votrient - US v/s Rest of World Annual Sales Value (US$ Million), 2019
  • Figure 26-163: Votrient - US v/s Rest of World Annual Sales Value (%), 2019
  • Figure 26-164: Votrient - Quarterly Sales Value (US$ Million), 2019
  • Figure 26-165: Panretin - FDA Approval & patent Expiration Year
  • Figure 26-166: Panretin - Price for 60gm Supply & Price per unit of Gel (US$), May'2020
  • Figure 26-167: Panretin - Minimum & Maximum Duration of Treatment (Weeks)
  • Figure 26-168: Lysodren - Price for 100 Tablets Supply & Price per unit of Tabalet (US$), May'2020
  • Figure 26-169: Lysodren - Minimum & Maximum Daily Dose (mg)
  • Figure 26-170: Valstar - FDA Approval & First Generic Approval Year
  • Figure 26-171: Valstar - Price for a Supply of 20ml & Price per ml of Intravesical Solution (US$), May'2020
  • Figure 26-172: Valstar - Cost of Single Treatment Cycle & Full Treatment (US$), May'2020
  • Figure 26-173: Hydroxyurea - FDA Approval & First Generic Approval Year
  • Figure 26-174: Hydrea - Price for a Supply of 100 Capsules & Price per unit Capsule (US$), May'2020
  • Figure 26-175: Generic Hydroxyurea - Price for a Supply of 100 Capsules & Price per unit Capsule (US$), May'2020
  • Figure 26-176: Generic Hydroxyurea - Dose Incrimination after Every 12 Weeks (mg/day)
  • Figure 26-177: Mitoxantron - FDA Approval & First Generic Approval Year
  • Figure 26-178: Mitoxantron - Price for 10ml, 12.5ml & 15 ml Supply of 2mg/ml Intravenous Solution (US$), June 2020
  • Figure 26-179: Mitoxantron - Minimum & Maximum Dose for Prostate Cancer (mg/3weeks)
  • Figure 26-180: Zometa - FDA Approval & First Generic Approval Year
  • Figure 26-181: Reclast - FDA Approval & First Generic Approval Year
  • Figure 26-182: Zometa - Price for 5ml Supply & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 26-183: Reclast - Price for 10ml Supply & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 26-184: Generic Zoledronic Acid - Price for 5ml and 200ml Supply of 4mg/ml Intravenous Solution (US$), June'2020
  • Figure 26-185: Generic Zoledronic Acid - Price for 100ml & Price per ml of 4mg/100ml Intravenous Solution (US$), June'2020
  • Figure 26-186: Generic Zoledronic Acid - Price for 100ml & Price per ml of 5mg/100ml Intravenous Solution (US$), June'2020
  • Figure 26-187: Fotemustine - Price for 4ml & Price per ml of Intravenous Vial (US$), May'2020
  • Figure 26-188: Fotemustine - Minimum & Maximum Duration of Rest Phase (Weeks)
  • Figure 26-189: Fotemustine - Duration of Induction & Maintenance Cycle (Weeks)
  • Figure 26-190: Nanoxel - DCGI Approval Year by Indication
  • Figure 26-191: Nanoxel - Price for 15ml Supply & Price per ml of Intravenous Solution (INR/US$), June'2020
  • Figure 26-192: Nanoxel - Price for 5ml Supply & Price per ml of Intravenous Solution (INR/US$), June'2020
  • Figure 26-193: Nanoxel - Minimum & Maximum Dose (mg/3weeks)
  • Figure 26-194: Hycamtin Injectable Solution - FDA Approval & First Generic Approval Year
  • Figure 26-195: Topotecan Capsule - FDA Approval & First Generic Approval Year
  • Figure 26-196: Generic Hycamtin - Price for supply of 4gm intravenous Powder & 4ml Intravenous Solution (US$), May'2020
  • Figure 26-197: Hycamtin - Cost of Single Treatment Cycle by Indication (US$), May'2020
  • Figure 26-198: Decogen - FDA Approval & first Generic Approval Year
  • Figure 26-199: Decitabine - Price for 50mg Branded & Generic Intravenous Powder (US$), May'2020
  • Figure 26-200: Decitabine - Cost of Single Dose, Single day & Single Treatment Cycle using 15mg/m2/Thrice a Day Dose regimen (US$), May'2020
  • Figure 26-201: Decitabine - Cost of Single Day & Single Treatment Cycle using 20mg/m2/Daily Dose regimen (US$), May'2020
  • Figure 26-202: Fotivda - Price for 21 Capsules & Price per unit Capsule (US$), June'2020
  • Figure 26-203: Fotivda - Recommended & Reduced Dose (Mcg)
  • Figure 26-204: Xermelo - Patent Issue & Expiration Year
  • Figure 26-205: Xermelo - Price for 56 Capsules & Price per unit Capsule (US$), June'2020
  • Figure 26-206: US - Xermelo sales Value (US$ Million), 2018 & 2019
  • Figure 26-207: US - Xermelo Quarterly Sales Value (US$ Million), 2019
  • Figure 26-208: Gleevec - FDA Approval by Dosage Form
  • Figure 26-209: Gleevec - FDA Approval by Indication
  • Figure 26-210: Gleevec - Patent Issue & Expiration Year
  • Figure 26-211: Imatinib - Price for 30 Tablet supply of Branded & Generic Imatinib 400mg (US$), May'2020
  • Figure 26-212: Imatinib - Price for 90 Tablet supply of Branded & Generic Imatinib 400mg (US$), May'2020
  • Figure 26-213: Gleevec - Recommended Dose by Indication (mg/Day)
  • Figure 26-214: Mekinist - FDA Approval by Indication
  • Figure 26-215: Mekinist - Number of Patents by Assignee
  • Figure 26-216: Mekinist - Patent Expiration Year by Assignee
  • Figure 26-217: Mekinist - Price for 30 Tablets & Price per Unit Tablet of 0.5mg (US$), May'2020
  • Figure 26-218: Mekinist - Price for 30 Tablets & Price per unit Tablet of 2mg (US$), May'2020
  • Figure 26-219: Mekinist - Recommended Initial Dose & dose After Reduction (mg/day), May'2020
  • Figure 26-220: Cabometyx - FDA Approval by Indication
  • Figure 26-221: Cabometyx - Patent Issue & Expiration Year
  • Figure 26-222: Cabometyx - Price for 30 Tablet Supply & Price per unit Tablet (US$), May'2020
  • Figure 26-223: Cabometyx - Recommended Initial Dose & Dose After Reduction (mg/day), May'2020
  • Figure 26-224: Cabometyx - Annual Sales Value (US$ Million), 2018 & 2019
  • Figure 26-225: Cabometyx - Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 26-226: Braftovi - FDA Approval by Indication
  • Figure 26-227: Braftovi - Number of Patents by Assignee
  • Figure 26-228: Braftovi - Patent Expiration Year by Assignee
  • Figure 26-229: Braftovi - Price for 180 Tablets & Price per unit Tablet (US$), May'2020
  • Figure 26-230: Braftovi - Recommended dose by Indication
  • Figure 26-231: Braftovi - Daily Treatment Cost by Indication (US$), May'2020
  • Figure 26-232: Tafinlar - FDA Approval by Indication
  • Figure 26-233: Tafinlar - Number of Patents by Assignee
  • Figure 26-234: Tafinlar - Patent Expiration Year by Assignee
  • Figure 26-235: Talfinlar - Price for 120 Tablets & Price per unit of 50mg Tablet (US$), May'2020
  • Figure 26-236: Talfinlar - Price for 120 Tablets & Price per unit of 75mg Tablet (US$), May'2020
  • Figure 26-237: Talfinlar - Recommended Dose & Dose after reduction (mg/day), May'2020
  • Figure 26-238: Sutent - FDA Approval by Indication
  • Figure 26-239: Sutent - Patent Issue & Expiration Year
  • Figure 26-240: Sutent - Patent Issue & Expiration Year
  • Figure 26-241: Sutent - Recommended Dose by Indication (mg/day)
  • Figure 26-242: Levoleucovorin - FDA Approval Year by Brand Name
  • Figure 26-243: Fusilev - Patent Issue & Expiration Year
  • Figure 26-244: Levoleucovorin - Price for Intravenous Powder by Brand name & Dose (US$), June'2020
  • Figure 26-245: Bendamustine - FDA Approval Year by Brand Name
  • Figure 26-246: Treanda - Patent Issue & Expiration Year
  • Figure 26-247: Bendeka - Number of Patent by Assignee
  • Figure 26-248: Bendeka - Patent Expiration Year by Assignee
  • Figure 26-249: Bendamustine - FDA & First Generic Approval Year
  • Figure 26-250: Bendamustine - Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 26-251: Bendeka - Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 26-252: Belrapzo - Price for 4 ml Sully & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 26-253: Bendamustine - Comparision of Treatment Cost of CLL uisng Branded & Generic Solution (US$), June'2020
  • Figure 26-254: Bendamustine - Comparision of Treatment Cost of CLL uisng Branded & Generic Solution (US$), June'2020
  • Figure 26-255: Talaporfin - Price for Various Supplies of Intravenous Powder (US$), June'2020
  • Figure 26-256: Tucidinostat - CFDA Approval Year by Indication
  • Figure 26-257: Epidaza - Price for Weekly & Monthly Treatment Supply (CNY/US$), June'2020
  • Figure 26-258: DC Beads - Price for 10ml Supply & Price per ml of 2mg/ml Solution (US$/GBP), June'2020
  • Figure 26-259: DC Beads - Cost of Single Procedure by Dosage Form (US$/GBP), June'2020
  • Figure 26-260: Temodar - FDA Approval Year by Dosage Form
  • Figure 26-261: Temodar - Patent Issue & Expiration Year
  • Figure 26-262: Temodex - Patent issue & Expiration Year
  • Figure 26-263: Temodar - Price for 6 Capsule Supply & Price per unit of various Dose Regimens (US$), May'2020
  • Figure 26-264: Temodar - Price for 14 Capsule Supply & Price per unit of various Dose Regimens (US$), May'2020
  • Figure 26-265: Temozolomide - Price for 6 Capsule Supply & Price per unit of various Dose Regimens (US$), May'2020
  • Figure 26-266: Temodar - Initial & Maintenance Dose for Anaplastic Astrocytoma (mg/m2)
  • Figure 26-267: Genexol-PM - Price for 100mg Vial (US$/INR), June'2020
  • Figure 26-268: Nanoxel M - Amount of Docetaxel by Vial
  • Figure 26-269: Methotrexate - Average Price of 10 ml Supply & Price per ml of 25mg/ml Intravenous Solution (US$), June'2020
  • Figure 26-270: Methotrexate - Average Price of Different Supplies of Oral Tablet (US$), June'2020
  • Figure 26-271: Methotrexate - Minimum & Maximum Duration of Initial Treatment Phase of ALL (Weeks), June'2020
  • Figure 26-272: Methotrexate - Single Treatment Cycle Cost in Initial & Maintenance Phase (US$), June'2020
  • Figure 26-273: Methotrexate - Minimum & Maximum Treatment Cost of Initial Phase of ALL (US$), June'2020
  • Figure 26-274: Methotrexate - Duration of Treatment & Rest Period for Choriocarcinoma Treatment (Days), June'2020
  • Figure 26-275: Methotrexate - Minimum & Maximum Treatment Cost of Single Day (US$), June'2020
  • Figure 26-276: Methotrexate - Minimum & Maximum Cost of Single Treatment Cycle (US$), June'2020
  • Figure 26-277: Trecondi - Price for 5 Vial Supply & Price per Vial of 1mg (GBP/US$), June'2020
  • Figure 26-278: Trecondi - Price for 5 Vial Supply & Price per Vial of 5mg (GBP/US$), June'2020
  • Figure 26-279: Treosulfan - Daily Adult Dose & Total Required Dose (g/m2), June'2020
  • Figure 26-280: Treosulfan - Minimum & Maximum Daily Pediatric Dose (g/m2), June'2020
  • Figure 26-281: Camtobell - Price for 2mg Intravenous Solution (KRW/US$), June'2020
  • Figure 26-282: Camtobell - Cost of Daily Treatment & Cost of One Treatment Cycle (KRW/US$), June'2020
  • Figure 26-283: Liposomal Paclitaxel - Approval Year by Brand Name
  • Figure 26-284: Amsacrine - Minimum & Maximum Recommended Dose (mg/m2)
  • Figure 26-285: Cyclophosphamide - FDA Approval Year by Companies
  • Figure 26-286: Cyclophosphamide - Average Price for 1gm, 2gm & 500mg Powder for Injection (US$), June'2020
  • Figure 26-287: Cyclophosphamide - Average Price for a Supply of 100 Capsules of 25mg & 50 mg Dose (US$), June'2020
  • Figure 26-288: Hikma's Cyclophosphamide - Average Price for a Supply of 100 Capsules of 25mg Dose (US$), June'2020
  • Figure 26-289: Cyclophosphamide IV Solution - Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June'2020
  • Figure 26-290: Cyclophosphamide Capsule - Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June'2020
  • Figure 26-291: DoceAqualip - Price for 20mg & 80mg Supply of Intravenous Injection (INR/US$), June'2020
  • Figure 26-292: Doceaqualip - Recommended Dose by Indication (mg/m2 /3weeks), June'2020
  • Figure 26-293: Aredia - Price for 10 ml Supply & Price per ml of Various Dose Regimens (US$), June'2020
  • Figure 26-294: Aredia - Price for Price for 30mg & 90mg Powder for Injection (US$), June'2020
  • Figure 26-295: Aredia - Cost of Single Treatment Cycle by Dosage Forms (US$), June'2020
  • Figure 26-296: Nedaplatin - Minimum & Maximum Recommended Dose (mg/m2), June'2020
  • Figure 26-297: Cytarabin - Price for 25ml & 50ml Supply of 20mg/ml Intravenous Solution (US$), June'2020
  • Figure 26-298 Cytarabin - Price for 20ml Supply of 100mg/ml Intravenous Solution (US$), June'2020
  • Figure 26-299 Depocyt - Price for 5ml Supply & Price per ml of 10mg/ml Intravenous Solution (US$), June'2020
  • Figure 26-300: Cytarabin - Average Minimum & Maximum Cost of Daily Treatment of Acute Nonlymphocytic Leukemia (US$), June'2020
  • Figure 26-301: Cytarabin - Average Daily & Full Treatment Cost in Initial Phase of Manengial Leukemia (US$), June'2020
目次

"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:

  • Small Molecule Cancer Drug Market Opportunity: More Than US$ 125 Billion by 2026
  • USA Dominates The Global Small Molecule Cancer Drug Market: >50% Share
  • Small Molecule Cancer Drug Market Clinical Trials: >2500 Drugs
  • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
  • Small Molecule Drug Insight by Cancer
  • Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
  • Covid-19 Impact On Small Molecule Cancer Drug Market

The small molecule drug centric approach has transformed the global cancer therapy market and has helped to decrease the mortality rate by overcoming the drawbacks of the traditional therapies such as chemotherapy, radiation therapy and others. The fundamental approach of using big molecular based drugs for the cancer treatment has now been shifted towards to small molecule drugs driven by multiple advantages over traditional or large molecules based drugs. The arrival of small molecule drugs in the cancer therapeutics landscape is not less than a massive breakthrough. From different radiation waves to immune cells, all have got settled in the cancer therapeutics market but the advent of small molecule drugs is however an accomplishment that is greater than any other major discovery in the cancer therapeutics market.

"Small Molecule Cancer Drug Market To Double In Next 6 Year Period To US$ 130 Billion Driven By New Drug Launches & Dynamic Clinical Pipeline"

An important parameter that should be associated with any of the cancer treatment is its specificity. Being specific to the cancer target is one of the most requisite and fundamental premise that decides whether the cancer therapy will result in inclination or declination of the mortality rate. The small molecule drug approach is quite specific and target oriented in functionality and has achieved interest of all stake holders from global cancer therapy market. The basic approach is to search for a specific molecular target and undergo the elimination of the cancer cells from the body. The small molecule cancer drug methodology is conceptually more specific than any of the available traditional non-targeted therapy as it provides a better target specificity and better reach to the cancer cells.

Other than all the commercially available cancer treatments, small molecule drugs are on the urge to provide a treatment strategy that has more success rate for overall survival. Many parameters are associated with the small molecule drugs that have made them quite promising for the use. Some of the parameters include: molecular size, availability, site of action, cell permeability and mode of administration. All of these factors are somehow responsible for the success that small molecule drugs have achieved in short period of time.

"Small Molecule Based Cancer Drugs Account For More Than 25% Of The Global Cancer Drug Pipeline"

As of now, small molecule drugs are considered as a special cancer therapy due to the advantages that are associated with it. In today's cancer therapeutics world, there are two therapies that undergo specific molecular targeting: monoclonal antibody and small molecule drugs. But there is also one parameter that is making small molecule drugs more preferable than the monoclonal antibodies is the size of small molecule drugs making it permeable to plasma membrane or cell membrane. From the different studies that have been performed under the cancer research domain, it has been confirmed that in case of different cancer types, there are receptors for target that are present inside the cell membrane. The presence of target inside the cell membrane makes it difficult for other drugs to penetrate or target the desired receptor. At this position, the usage of small molecule drugs is necessary as it has the ability to cross the cell membrane due to small size and target the cancer receptor that is present inside the cell membrane.

The small molecule drugs have the ability to target different mechanisms through which cancer develops and grows. An important mechanism through cancer is developed is by controlling all the growth factors required for the growth and development of the cells. As it has been well-studied that there are certain growth factors that are responsible for different mechanisms in the body and by controlling the mechanism of growth factor, cancer can easily surpass all the factors that can lead to its eradication.

The future market scenario looks promising for the research, development and commercial viability of small molecule based cancer drugs. The basic targeting advantage along with the dominance of small molecule drugs in cancer clinical pipeline will drive the global small molecule cancer drug market in coming years. The market is expected to double its revenue to US$ 130 Billion by 2026 and will continue to outperform the others available drug therapies for the treatment of cancer malignancies.

Table of Contents

1. Introduction to Small Drug Molecule

2. Need for Small Molecule Drug

3. Comparison of Cancer Small Molecule Drugs with Other Available Therapies

  • 3.1. Small Molecule Cancer Drugs & its Comparison with Other Drugs Parameters
  • 3.2. Small Molecule Cancer Drug vs. Immunotherapy
  • 3.3. Small Molecule Cancer Drugs vs. Chemotherapy
  • 3.4. Small Molecule Cancer Drug vs. Radiation Therapy
  • 3.5. Small Molecule Cancer Drugs vs. Surgical Removal of Cancer Cells

4. Small Drug Molecule as Emerging Cancer Therapeutics

  • 4.1. Small Molecule Drugs & its Relation with Cancer Treatment
  • 4.2. Mechanisms Targeted by Small Molecule Drugs in Cancer Therapy
    • 4.2.1. Small Molecule Drugs as Growth Factor Kinase Inhibitor for Cancer Therapy
    • 4.2.2. Small Molecule Drugs as DNA Damage Response Inhibitors for Cancer Therapy
  • 4.3. Small Molecule Inhibitors & their Related Pathways

5. Global Trends & Opportunities for Small Molecule Cancer Drug Market

  • 5.1. US
  • 5.2. Europe
  • 5.3. Asia
  • 5.4. Rest of World

6. Global Small Molecule Cancer Drug Clinical Pipeline Overview

  • 6.1. By Phase
  • 6.2. By Formulation
  • 6.3. By Company
  • 6.4. By Country
  • 6.5. By Indication
  • 6.6. By Mechanism of Action

7. Global Analysis for Small Molecule Cancer Drug Research Work at Educational Level

  • 7.1. IACS-10759 Small Molecule Drug Discovery at MD Anderson
  • 7.2. BET Small Molecule Inhibitor Discovery by Yale Researchers for the Cancer Patients
  • 7.3. Amgen & Mirati's Small Molecule Cancer Drug against KRAS Gene in Different Cancer Types
  • 7.4. AOH1160 Small Molecule Research to Focus Breast Cancer at University of California

8. Global Analysis for Partnerships, Collaborations for Expanding Small Molecule Cancer Drug Market

  • 8.1. IACS & X-Chem to Undergo Small Molecule Cancer Therapies Development
  • 8.2. MD Anderson, Artios Pharma & ShangPharma to Collaborate for Small Molecule ATR Inhibitor Program
  • 8.3. Aptose Biosciences & Moffitt Cancer Center to Undergo Strategic Collaboration for the Development of New Multi-Targeting Epigenetic Therapeutic Agents
  • 8.4. Merck & Taiho to Collaborate for Small KRAS- Targeting Cancer Drugs

9. Drivers & Challenges Associated with the Small Molecule Cancer Drug Market

  • 9.1. Potential Insights about Factors Driving the Small Molecule Cancer Drug Market at Global Level
  • 9.2. Challenges Concerning the Growth of Small Molecule Cancer Drug Market

10. Future Insights for Small Molecule Cancer Market in Cancer Research Area

11. Covid-19 Impact On Small Molecule Cancer Drug Market

12. Small Molecule Drugs for Breast Cancer - Availability, Dosage & Price Analysis

  • 12.1. Ribociclib (Kisqali)
  • 12.2. Alpelisib (Piqray)
  • 12.3. Abemaciclib (Verzenio)
  • 12.4. Talazoparib (Telzenna)
  • 12.5. Nertinib (Nerlynx)
  • 12.6. Palbociclib (Ibrance)
  • 12.7. Ixabepilone (Ixempra)
  • 12.8. Anastrazole (Arimidex)
  • 12.9. Lapatinib (Tykerb)
  • 12.10. Toremifene (Fareston)
  • 12.11. Letrozole (Femara)
  • 12.12. Raloxifene (Evista)
  • 12.13. Tamoxifen Oral Liquid (Soltamax)
  • 12.14. Exemestane (Aromasin)
  • 12.15. Testosterone Cypionate (Depo-Testosterone)
  • 12.16. Fluoxymesterone (Halotestine/Androxy)
  • 12.17. Fadrozole (Afema)
  • 12.18. Tamibarotene (Amnolake)
  • 12.19. Testosterone Propionate

13. Small Molecule Drugs for Leukemia Cancer - Availability, Dosage & Price Analysis

  • 13.1. Gilteritinib (Xospata)
  • 13.2. Venetoclax (Venclexta)
  • 13.3. Bosutinib (Bosulif)
  • 13.4. Nilotinib (Tasigna)
  • 13.5. Tretinoin (Vesanoid)
  • 13.6. Clofarabine (Clolar)
  • 13.7. Cytarabine/Daunorubicin (Vyxeos)
  • 13.8. Dasatinib (Sprycel)
  • 13.9. Ponatinib (Iclusig)
  • 13.10. Enasidenib (Idhifa)
  • 13.11. Ivosidenib (Tibsovo)
  • 13.12. Cladribine (Mavenclad/Leustatin)
  • 13.13. Mercaptopurine Oral Suspension (Purixan)
  • 13.14. Methotrexate Oral Solution (Xatmep)
  • 13.15. Pentostatin (Nipent)
  • 13.16. Arsenic Trioxide (Trisenox)
  • 13.17. Quizartinib (Vanflyta)
  • 13.18. Histamine Dihydrochloride Injection (Ceplene)
  • 13.19. Ubenimix (Bestatin)
  • 13.20. Omacetaxine Mepesuccinate (Synribo)
  • 13.21. Radotinib (Supect)

14. Small Molecule Drugs for Lung Cancer - Availability, Dosage & Price Analysis

  • 14.1. Gefitinib (Irresa)
  • 14.2. Entrectinib (Rozlytrek)
  • 14.3. Osimertinib (Tagrisso)
  • 14.4. Erlotinib (Tarceva)
  • 14.5. Brigatinib (Alunbirg)
  • 14.6. Lorbrena (Lorlatinib)
  • 14.7. Vinorelbine (Navelbine)
  • 14.8. Zykadia (Certinib)
  • 14.9. Pemetrexed (Alimta)
  • 14.10. Alectinib (Alecensa)
  • 14.11. Xalkori (Crizotinib)
  • 14.12. Nintedanib (Ofev)
  • 14.13. Anlotinib (Focus V)
  • 14.14. Amrubicin (Calsed)
  • 14.15. Icotinib (Conmana)

15. Small Molecule Drugs for Lymphomas - Availability, Dosage & Price Analysis

  • 15.1. Copanlisib (Aliqopa)
  • 15.2. Methoxsalen Solution (Uvadex)
  • 15.3. Pralatrexate (Folotyn)
  • 15.4. Bexarotene Topical (Targretin Gel)
  • 15.5. Pixantrone (Pixuvri)
  • 15.6. Belinostat (Beleodaq)
  • 15.7. Zanubrutinib (Brukinsa)
  • 15.8. Vorinostat (Zolinza)
  • 15.9. Romidepsin (Istodax)
  • 15.10. Bexarotene (Targretin)
  • 15.11. Mechlorethamine (Valchlor/Ledaga)

16. Small Molecule Drugs for Myeloma - Availability, Dosage & Price Analysis

  • 16.1. Ixazomib (Ninlaro)
  • 16.2. Melphalan Intravenous (Evomela/Chemostat)
  • 16.3. Thalidomide (Thalomid)
  • 16.4. Selinexor (Xpovio)
  • 16.5. Panobinostat (Farydak)
  • 16.6. Bortezomib (Velcade)
  • 16.7. Pomalidomide (Pomalyst)
  • 16.8. Dexamethasone High Dose (Neofordex)

17. Small Molecule Drugs for Prostate Cancer - Availability, Dosage & Price Analysis

  • 17.1. Xtandi (Enzalutamide)
  • 17.2. Apalutamide (Erleada)
  • 17.3. Ertafitinib (Balversa)
  • 17.4. Darolutamide (Nubeqa)
  • 17.5. Bicalutamide (Casodex)
  • 17.6. Nilutamide (Nilandron)
  • 17.7. Abiraterone (Zytiga)
  • 17.8. Xofigo (Radium Ra 223 dichloride)
  • 17.9. Pedeliporfin (Tookad)

18. Small Molecule Drugs for Gastric Cancer - Availability, Dosage & Price Analysis

  • 18.1. Avapritinib (Ayvakit)
  • 18.2. Rivoceranib (Aitan)
  • 18.3. Gimeracil/Oteracil/Tegafur (Teysuno/TS-1)
  • 18.4. Eptaplatin/Heptaplatin

19. Small Molecular Drugs For Cancer Diagnosis - Availability, Dosage & Price Analysis

  • 19.1. Fluciclovine 18F (Axumin)
  • 19.2. Tc 99m Tilmanocept (Lymphoseek)
  • 19.3. Perflubutane (Sonazoid)
  • 19.4. Hexyl Aminolevulinate (Cysview)
  • 19.5. Fluorocholine 18F (IASOcholine/Pcolina)
  • 19.6. Gadobuterol (Gadavist)

20. Small Molecule Drugs for Skin Cancer - Availability, Dosage & Price Analysis

  • 20.1. Benimetinib (Mektovi)
  • 20.2. Cobimetinib (Cotellic)
  • 20.3. Sonidegib (Odomzo)
  • 20.4. Vismodegib (Erivedge)
  • 20.5. Imiquimod (Aldara/Zyclara)
  • 20.6. Amivolevulinic Acid (Ameluz)
  • 20.7. Methyl Aminolevulinate (Metvixia/Metvix PDT)
  • 20.8. Vemurafenib (Zelboraf)

21. Small Molecule Drugs for Pancreatic Cancer - Availability, Dosage & Price Analysis

  • 21.1. Irinotecan Liposome Injection (Onivyde)

22. Small Molecule Drugs for Thyroid Tumors - Availability, Dosage & Price Analysis

  • 22.1. Vendetanib (Caprelsa)

23. Small Molecule Drugs for Renal Cancer - Availability, Dosage & Price Analysis

  • 23.1. Axitinib (Inlyta)

24. Small Molecule Drugs for Colorectum Cancer - Availability, Dosage & Price Analysis

  • 24.1. Tipiracil/Trifluridine (Lonsurf)
  • 24.2. Irinotecan (Camptosar)
  • 24.3. Oxaliplatin (Eloxatin)
  • 24.4. Raltitrexed (Tomudex)
  • 24.5. Irinotecan-Eluting Beads (Paragon Beads/Debiri)
  • 24.6. Fruquintinib (Elunate)

25. Small Molecule Drugs for Solid Tumors - Availability, Dosage & Price Analysis

  • 25.1. Larotectinib (Viktravi)

26. Small Molecule Drugs Targeting Multiple Cancer - Availability, Dosage, Price & Sales Analysis

  • 26.1. Fludarabin (Fludara/Oforta)
  • 26.2. Gemcitabine (Gemzar)
  • 26.3. Sorafnib (Nexavar)
  • 26.4. Rucaparib (Rubraca)
  • 26.5. Doxorubicin (Aridamycin)
  • 26.6. Acalabrutinib (Calquence)
  • 26.7. Ibrutinib (Imbruvica)
  • 26.8. Azacitidine (Vidaza)
  • 26.9. Lenalidomide (Revlimid)
  • 26.10. Doxorubicin Liposomal (Doxil)
  • 26.11. Tazemetostat (Tazverik)
  • 26.12. Busulfan (Busulfex)
  • 26.13. Afatinib (Gilotrif)
  • 26.14. Gemcitabine (Infugem)
  • 26.15. Carmustine Polifeprosan 20 wafer (Gliadel)
  • 26.16. Eribulin (Halaven)
  • 26.17. Paclitaxel-Protein Bound (Abraxane)
  • 26.18. Trabectedine (Yondelis)
  • 26.19. Paclitaxel (Taxol)
  • 26.20. Docetaxel (Taxotere)
  • 26.21. Idelalisib (Zydelig)
  • 26.22. Duvelisib (Copiktra)
  • 26.23. Regorafenib (Stivagra)
  • 26.24. Nelarabine (Arranon)
  • 26.25. Capecitabine (Xeloda)
  • 26.26. Lenvatinib (Lenvima)
  • 26.27. Olaparib (Lynparza)
  • 26.28. Niraparib (Zejula)
  • 26.29. Pazopanib (Votrient)
  • 26.30. Alitretinoin Topical (Panretin)
  • 26.31. Mitotane (Lysodren)
  • 26.32. Valrubicin (Valstar)
  • 26.33. Hydroxyurea (Hydrea)
  • 26.34. Mitoxantrone (Novantrone)
  • 26.35. Zoledronic Acid (Zometa/Reclast)
  • 26.36. Fotemustine (Muforan)
  • 26.37. Paclitaxel Nanoparticle (Nanoxel)
  • 26.38. Topotecan (Hycamtin)
  • 26.39. Decitabine (Decogen)
  • 26.40. Tivozanib (Fotivda)
  • 26.41. Telotristat Etiprate (Xermelo)
  • 26.42. Imatinib (Gleevec)
  • 26.43. Trametinib (Mekinist)
  • 26.44. Cabozantinib (Cabometyx)
  • 26.45. Encorafenib (Braftovi)
  • 26.46. Dabrafenib (Tafinlar)
  • 26.47. Sunintab (Sutent)
  • 26.48. Levoleucovorin (Fusilev/Khapzory)
  • 26.49. Bendamustine (Treanda/Belrapzo/Bendeka)
  • 26.50. Forodesine (Fodosine/Mundesine)
  • 26.51. Talaporfin (Laserphyrin)
  • 26.52. Tucidinostat (Epidaza)
  • 26.53. Doxorubicin Eluting Beads (DC Beads)
  • 26.54. Temozolomide (Temodar)
  • 26.55. Paclitaxel Polymeric Micelle Formulation (GenexolPM)
  • 26.56. Docetaxel polymeric micelle (Nanoxel M)
  • 26.57. Methotrexate
  • 26.58. Treosulfan (Ovastat/Tercondi)
  • 26.59. Belotecan (Camtobell)
  • 26.60. Paclitaxel Liposomal(Lipusu/Bevetex)
  • 26.61. Amsacrine (Amsa PD/Amekrin)
  • 26.62. Cyclophosphamide
  • 26.63. Docetaxel Nanosome (DoceAqualip)
  • 26.64. Pamidronic acid (Aredia)
  • 26.65. Mopidamol (Rapenton)
  • 26.66. Nedaplatin (Aqupla)
  • 26.67. Cytarabin/Cytarabin Liposomal (DepoCyt)
  • 26.68. Dianhydrogalactitol (DAG for Injection)

27. Competitive Landscape

  • 27.1. Johnson & Johnson
  • 27.2. Teva Pharmaceutical
  • 27.3. Boehringer Ingelheim
  • 27.4. Allergan
  • 27.5. Pfizer
  • 27.6. Bristol-Myers Squibb
  • 27.7. Merck
  • 27.8. GlaxoSmithKline
  • 27.9. AstraZeneca
  • 27.10. Gilead Sciences